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According to international human genome sequencing consortium 2004[43], it was known that only 
less than 2% of the total human genome code for proteins. This ignited quite a surprise in the 
scientific community. Since then, a lot of researchers are attracted towards the noncoding part of the 
genome. There are explosion of researches addressing the role of the 98% of the human untranslated 
regions of the genome. This shows that the transcription is not only limited to the protein coding 
regions of the genome rather more than 90% of the genome are likely to be transcribed. [43] This 
will result in the transcription of tens and thousands of the long noncoding RNAs (lncRNAs) with 
little or no coding potential. However, the molecular mechanism and function of long noncoding 
RNAs are still an open research topic. Although the functions of limited lncRNAs are identified, there 
is still a gap in identifying the function of novel lncRNAs. 
 
This project implements different computational methods to predict the function of novel lncRNAs 
identified from TCGA glioblastoma multiforme samples. The methods used in this functional 
prediction include both expression and sequence-based analysis approach. In expression-based 
analysis, the co-expressing genes with lncRNAs are used to predict the possible functional relation.  
In sequence based analysis, the gene-protein and lncRNA-protein interactions together with miRNA-
lncRNA interactions are considered towards the possible functional predictions. 
 
The result from the integrated functional prediction on the novel lncRNAs show that TCGA_gbm-3-
153501 novel lncRNA which is co-expressed together with the THBS1 gene with correlation 
coefficient of more that 0.5 is predicted to function in cell-cell and cell-to-matrix interactions, platelet 
aggregation, angiogenesis, and tumorigenesis. [202] MSI1, RBM3 and RBM8A are RNA binding 
proteins (RBPs) that have binding site on both the first top five differentially expressed lncRNAs 
which are TCGA_gbm-2-104096501, TCGA_gbm-3-153501, TCGA_gbm-5-63687001 and TCGA_gbm-17-
10671251 and IGF2 which is among the top 10 differentially expressed genes. Therefore, these 
lncRNAs are predicted to have functional role in cell proliferation and maintenance of stem cells in 
the central nervous system.  
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TERMS AND ABBREVIATIONS 
 
DNA Deoxyribonucleic acid 
RNA Ribonucleic acid 
siRNA Small interfering 
snoRNA Small nucleolar RNAs 
miRNA microRNA 
rRNA Ribosomal RNA 
LncRNA long noncoding RNA 
LincRNA long intergenic RNA 
mRNA messenger RNA 
ENCODE The Encyclopedia of DNA Elements 
FANTOM Functional Annotation Of Mammalian genome 
cDNA Complementary DNA 
LNCipedia Database for annotated human lncRNA transcript 
Sequences and structures 
ORF Open reading frame 
HOTAIR HOX transcript antisense RNA 
RNA splicing Modification of the nascent pre-messenger RNA (pre-
mRNA) transcript in which introns are removed and 
exons are joined 
Chromatin remodeling Dynamic modification of chromatin architecture                                                                             
to allow access of condensed genomic DNA 
RNA-seq RNA sequencing 
 vii 
SAGE A sequencing technology capable of producing large 
number of short sequence tags identifying both known 
and unknown transcripts 
GENCODE Part of the pilot phase of the ENCODE project to identify    
and map all protein-coding genes within from ENCODE 
project. 
MSigDB Molecular Signatures Database 
Onco-lncRNAs Cancer causing long noncoding RNAs 
Apoptosis A process of programmed cell death 
catRAPID Algorithm to estimate the binding propensity of protein-
RNA pairs 
MCL Markov cluster algorithm 
MALAT1 Metastasis associated lung adenocarcinoma transcript 1 
GBM Glioblastoma multiforme 
Novel transcript The transcripts that has not been observed before 
Promoter A region in DNA that initiates the transcription of the 
particular gene 
Exon Part of the gene that becomes the final mature mRNA. 
Intron non coding sections of an premature mRNA transcript 
Start codon The first triplet of nucleotides on mRNA to be translated 
by rRNA 
Stop codon A nucleotide triplet that ignites the termination of 
translation in mRNA 
PWM Position weight matrix 
PFM Position frequency matrix 
Mutual information The measure of variable’s mutual dependency. 
Chromosome A structure in a cell that contain the DNA molecules. 
Human cells hold 23 pairs of chromosomes. 
 viii 
DEesq2 Differential expression analysis algorithm for high 
throughput count data such as RNA-seq 
RPKM Reads per kilobase pairs per million of mapped reads, a 
normalization method in sequencing count data. 
p-value  The measure of statistical significance in the hypothesis 
testing. 
RBP RNA binding proteins 
miRanda A software package to predict the microRNA target 
proteins 
3’ UTR A section of mRNA that immediately follows the 
translation termination codon 
5’ UTR The region in mRNA that is directly upstream from start 
codon. 
KEGG Database resource for understanding high-level functions 
and utilities of the biological system. 
RBPDB RNA binding protein database. 
hDPI Human DNA-protein interaction database 
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1 INTRODUCTION 
 
Ribonucleic acid (RNA) is one of the three basic biological macromolecules that constitute living cells 
alongside with deoxyribonucleic acid (DNA) and protein.  The flow of genetic information originates 
at DNA to be transcribed or copied to the RNA and then translated into protein. Proteins play the 
central role in all cellular endeavors of living things, ranging from playing important role as an 
enzyme, structural component of the cell and in cell signal transduction.   
 
DNA is a blueprint that holds all information regarding the cell and the RNA is a photocopy of the part 
of DNA. When the cell is in need of a certain protein, it turns on the portion of DNA or gene that codes 
for the particular protein. The RNA copies the information as mRNA.  The genetic code in mRNA then 
translated into protein using the cell’s protein manufacturing machinery, ribosome, which is 
composed of ribosomal RNA (rRNAs). 
 
Not all transcripts that copy genetic information from DNA can be translated into protein.  
Surprisingly, 97% of transcribed transcripts are non-protein coding. In general RNA can be 
categorized into two: protein-coding RNA and non-protein coding RNA (ncRNA).  Protein coding 
RNA, which is mRNA, has been the central topic of interest for long period of time in the field of 
molecular biology. Considering the change in the concentration of mRNA at the transcript level and 
the defect in protein synthesis are widely researched topic. Transcriptional and translational defects 
were assumed due to the mutation, chromosomal aberration or DNA damages at the genomic level. 
The non-protein coding RNAs were also considered to be only the building block of transfer RNA 
(tRNA), which acts as an adapter that bridges the mRNA sequence & the amino acid produced during 
translation and structural component of ribosomal RNA (rRNA) that acts as a protein manufacturing 
machinery in a cell.    
 
But in recent years, researches have shown that non-coding RNAs can act as enzymes, carrier for viral 
genetic information and regulation of different cellular process ranging from cell division, cell 
differentiation, cell growth, cell aging and apoptosis. There are different types of non-coding RNAs 
that specialized in particular functions in a cell. For example, microRNA (micrRNA) regulates the 
translation of mRNA by binding to 3’UTR region of the mRNA or in combination with small interfering 
RNA (siRNA), it causes the degradation of target mRNAs.  Small nucleolar RNAs (snoRNA) act on 
modification of small nuclear RNA (snRNAs), whose primary function is in the processing of the pre 
mRNA, mRNAs and rRNA in ribosome biogenesis. 
 
The other non-coding RNA that has attracted the attentions of many researchers recently is a long 
noncoding RNA (lncRNA), which is different from the other ncRNAs in that it has a longer nucleotide 
base, about 200 or longer. The whole-transcriptome analysis revealed vast number of lncRNAs. 
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Significant numbers of lncRNA are involved in various biological functions. Yet most of them are not 
annotated and the functional and molecular mechanisms have not been known.  As the numbers of 
discovered lncRNA are huge, it is difficult to experiment the functionality of lncRNA in the laboratory 
for all of them. Hence, the need to implement computational method to predict the functionality of 
different lncRNAs is vital. The goal of this thesis project is to fill the gap on computational functional 
prediction for lncRNA by integrating the gene expression and the newly identified lncRNAs 
expression in search of the co-expressing genes and novel lncRNAs together with the sequence based 
DNA-protein, lncRNA-protein and miRNA-lncRNA interaction. 
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2 BACKGROUND 
 
LncRNAs are RNAs that have length of 200 nucleotides or more without protein-coding potential. It 
can be distinguished from small RNAs, such as microRNA, siRNA, snRNA and snoRNAs, by its length 
and from mRNA by its coding potential [3]. The genomic origin, subcellular compartmentalization 
and modifications of RNA reveal its possible functionality [2]. Out of all transcribed nucleotide bases, 
79.6% can be mapped back to the nuclear long RNAs while 15.1% are exclusively cytosolic long RNA 
as it is shown in the figure 1B [2].  5.3% of the sequences are also exclusively small RNAs as it is 
shown in figure 1A.   
 
 
 
Figure 1. The nuclear and cytosolic distribution of lRNA & sRNA in human genome [2] 
 
 
Although lncRNAs are such an abundant transcript in the genome, limited numbers of them are 
annotated.  Recently, there has been a project that aims to create a catalog of lncRNAs and 
information on their tissue specific expression. According to ENCODE database version 3.0, there are 
73,370 lncRNA entries from 1,239 organisms. Among these, only less than 200 were functionally 
annotated. [10] In 2000, the FANTOM [4] consortium discovered set of 34,030 lncRNAs catalog for 
mouse genome from the cDNA sequencing. [4] In 2010, 5446 lncRNAs catalog for the human genome 
are manually annotated. [5, 7] As to August 28, 2014, the LNCipedia 3.0 database contains the 
annotations for 113,513 human lncRNAs. [8, 9] 
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2.1 Calcification of lncRNA  
 
LncRNAs are believed to play roles in transcription, translation, protein localization, cellular 
structure integrity, imprinting, cell cycle & apoptosis, stem cell pluripotency, reprogramming heat 
shock response, cancer progression and development of other diseases. In order to perform 
functional studies on lncRNAs, it is important to see the different category of lncRNAs. LncRNAs are 
classified into several categories depending on the genomic location and context, the effects exerted 
on DNA sequence, functional mechanism and targeting mechanism. [10] 
 
2.1.1 Genomic location and context 
 
Based on the genomic location and context, the lncRNAs can be classified as an intergenic long non-
coding RNA (lincRNAs) and intronic long noncoding RNA.  LincRNAs are long noncoding RNAs that 
are transcribed from the non-coding part of the DNA between the two protein coding genes as it is 
illustrated in figure 2A. Structurally, lincRNAs are similar with the protein coding genes. They are 3’ 
polyadenylated, 5’ capped and exhibit the transcriptional activation. [10] But they don’t have an open 
reading frame (ORF) and they don’t code for protein. LincRNAs are the largest class of the non-coding 
RNA molecules in the human genome. In 2011, annotation catalog with 4662 human lincRNAs are 
created. [6, 7] 
 
Long noncoding RNA transcripts that are transcribed from the intron parts of the protein coding 
genes are intronic long noncoding RNAs as it is shown in figure 2B. Most of the intronic lncRNAs have 
the same tissue expression patterns as that of the corresponding protein coding genes. Hence, they 
may stabilize protein-coding transcripts or regulate their alternative splicing. [11] 
 
The transcription of intronic and intergenic long noncoding RNAs are regulated in different 
transcription activation mechanism. As a result, they may have different poly (A) modification and 
exhibit activities in different cellular localization. A small portion of intronic lncRNA’s function is 
studied in contrast with the lincRNAs that function through different mechanisms including cis or 
trans transcriptional regulation, translational control, splicing regulation, and other post-
transcriptional regulation. [10] 
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Figure 2. Classifications of lncRNAs [10] 
 
The other category of lncRNAs based on the genomic location and context are sense and antisense 
lncRNAs. Sense lncRNAs are the ones that are transcribed from the sense strand of the protein-coding 
gene containing the exons as it is illustrated in figure 2C. In contrast, the antisense lncRNAs are the 
ones that are transcribed from the antisense strands of the protein-coding gene. The sense strand of 
the DNA is the strand that has the same sequence as that of transcribed mRNA while the antisense 
strand is the DNA strand that is used as a template during transcription. [10] 
 
Yet another category of the lncRNA based on the genomic location and context is bidirectional 
lncRNA. This type of lncRNA sequence is transcribed from the opposite strand of the protein-coding 
gene whose transcription initiation site is less than 1000 base pair away. [12] 
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2.1.2 Effects exerted on the DNA sequence 
 
Based on the effects exerted on the DNA sequences, lncRNAs can also be classified into cis and trans 
lncRNAs. As significant number of lncRNAs are involved in the transcriptional regulation, cis-
lncRNAs are involved in regulation of gene expression in the close proximity while the trans-lncRNAs 
are the ones that involve in remote regulation of gene expression. [10] 
 
Cis-lncRNA regulates the expression of the nearby gene by transcriptional interference or chromatin 
modification mechanism. The transcriptional interference takes place as the lncRNA binds to the 
promoter of the target gene to block the PIC (preinitiation complex) formation or by the interaction 
of the lncRNA with the transcription factor. Such cis-lncRNAs are transcribed from the promoter 
region of the genes. [10] 
 
Cis-lncRNAs that function through the chromosomal modifications usually recruit the chromatin 
modification complex such as PRC (polycomb repressive complex) or Rpd3S HDAC (Rpd3 small 
histone deacetylase complexes). [10] PRC is the most studied chromatin modification complex. X 
inactive-specific transcript (Xist), the human 19 kb lncRNA, binds to PRC2 to induces the H3K27me3 
modification to make a transcriptional silencing in X chromosomes. In figure 3, L1 & L3 are labeled 
to be cis-lncRNAs. [10] 
 
Trans-lncRNAs act in trans-acting mode to target distant gene loci. For example, HOTAIR (HOX 
antisense intergenic RNA), which is approximately 2.2 kb pair long,  lncRNA that is transcribed from 
the HOXC (homeobox C cluster) gene locus in chromosome 12, can be transported by the Suz-Twelve 
protein to regulate the homologous target sites at HOXD (homeobox D cluster) gene locus in 
chromosome 2. [10] The trans-lncRNAs function independently of sequence complementary to target 
the gene loci. Trans-lncRNAs binds to the transcription elongation factors or RNA polymerases in 
addition to the chromatin modification complex to affect transcription. For example, lncRNA, B2 SINE 
RNA, has been found to bind the polymerase II complex to block its activity during heat shock 
response. [10] 
 
2.1.3 Cellular molecular mechanism 
Based on the cellular molecular mechanism, lncRNAs can also be classified into those that affect the 
transcriptional regulation, post-transcriptional regulation and other functions. lncRNAs that involve 
in the transcriptional regulation function in two mechanisms. The first one is transcriptional 
interference 
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Figure 3. Functional mechanism of lncRNA [10] 
 
mechanism.  As it is illustrated in the figure 3A, L1 is a cis-lncRNA that is transcribed from the 
promoter region of gene A and it binds to the promoter regions of gene A to block the binding of 
transcription factors. Hence, L1 is acting in transcriptional interference mechanism affecting the 
transcriptional initiation of gene A. In the same way L2 influences the transcription of gene B by 
interacting with the transcription factors and RNA polymerase as it is illustrated in figure 3A. 
 
The second transcriptional regulation functional mechanism is chromatin remodeling.  As it is shown 
in the figure 3A, lncRNA L3, functions to modify the chromatin protein by recruiting the chromatin 
modification complex PRC2. 
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In post-transcriptional regulation, lncRNAs are actively involved in the splicing regulation and 
translational control as it is shown in figure 3B.  LncRNAs that involve in splicing regulation may 
influence the splicing of mRNA by binding to the splicing factors or by directly hybridizing with 
mRNA sequence to block the splicing. For example, MIAT (myocardial infarction associated 
transcript), which is approximately 9–10 kb long lncRNA, binds to SF1 (splicing factor 1) to inhibit 
splicing and spliceosomal complex formation. [10] In the same way, Malat1 (metastasis-associated 
lung adenocarcinoma transcript 1),  which is approximately 7 kb long lncRNA, can bind to SR splicing 
factor [serine–arginine (SR)-rich splicing factor] and regulate its distribution in nuclear speckle 
domains. [10] Malat1 also influences the alternative splicing of pre-mRNAs. [10] 
 
Those lncRNAs that function in translational control may function either in binding to the 
translational factors or ribosomes. There are two lncRNAs, BC1 (brain cytoplasmic RNA 1) and BC200 
(200 nt brain cytoplasmic RNA), which can bind to eIF4A (eukaryotic translation initiation factor 4A), 
PABP (poly (A)-binding protein) and other factors, to repress translation initiation by blocking 
assembly of the required complex. [10]  snaR (small NF90-associated RNAs), a cytoplasmic lncRNAs 
and Gadd7 (growth arrested DNA-damage inducible gene 7) bind to the ribosome to influence the 
translation of mRNA. [10] 
 
Besides from the splicing and translational control mechanism, there are other post-translational 
mechanisms that are utilized by the lncRNAs.  lncRNAs involved in the process of siRNA (small 
interfering RNA) mechanism and interact with the miRNA to stabilize the target mRNA as it is shown 
in figure 3B.  Such kind of lncRNAs are called ceRNAs (competing endogenous RNAs). For instance, 
linc-MD1 (long intergenic ncRNA that is associated with muscle differentiation), which is 
approximately 0.5 kb pair long lncRNA, acts as sponge/target mimic of miR-133 and miR-135 to 
regulate the expression of two transcription factors: MAML1 (mastermind-like protein 1) and MEF2C 
(myocyte-specific enhancer factor 2C), which activate the expression of muscle-specific genes. [10] 
 
LncRNAs may also function as a natural antisense inhibitors to promote degradation of mRNA as it 
is shown in figure 3B.  It has been found that 21A, which is approximately 300 bp long lncRNA, which 
shows high sequence homology to CENP-F (centromere protein F) intronic portions, can reduce 
CENP-F expression at both mRNA and protein level through antisense inhibitor.[13] 
 
The other functional mechanism of lncRNAs beside the transcriptional and post-transcriptional 
regulation, are the protein localization, telomerase replication and RNA interference as it is shown in 
the figure 3C. [10] 
 
2.1.4 Targeting mechanism 
 
 9 
The last criterion to classify lncRNAs is based on their targeting mechanisms. Based on their targeting 
mechanism, lncRNAs are classified into signal, decoy, guide and scaffold lncRNAs. The signal lncRNA 
shows the cell type specific expression and its transcription is to deliver response to the stimuli. The 
decoy lncRNA binds and titrates away the protein target but does not exert any additional function. 
The guide lncRNA binds to protein to direct the localization of the ribonucleoprotein complex to 
specific target. The scaffold lncRNAs serve as a platform to bring multiple proteins together to form 
a ribonucleoprotein complex. [10] 
 
However, one lncRNA might have several targeting mechanism that the mode of action does not 
solely drawn from a single targeting mechanism. For example, Xist, Air, COLDAIR, HOTTIP, HOTAIR 
and  lincRNA-p21 lncRNAs operate in a dual mode as both signal and decoy lncRNAs. Some lncRNAs 
such as HOTAIR have more than two archetype or targeting mechanisms: anatomic signal, guiding 
the chromatin-modifying complexes to the target gene, and as a scaffold for PRC2 and LSD1. [10] 
 
The other way to categorize the lncRNAs are based on the type of interaction they make with their 
targets such as RNA-RNA pairing, RNA-DNA hybrids, RNA structure mediated interactions, and 
protein linkers. 
2.2 Molecular mechanism of lncRNA 
 
Unlike other small noncoding RNAs, which are highly conserved and function via transcriptional and 
posttranscriptional gene silencing through specific base pairing with their targets, lncRNAs are 
poorly conserved and involved in gene regulation by diverse mechanisms that are not fully known 
yet.  But, it is generally believed that lncRNAs may function by interacting with DNA, RNA and protein 
molecules and has four types of archetype that play roles as signal, decoy, scaffold and guide in the 
cell. 
 
2.2.1 Signal 
 
One of the molecular mechanisms for lncRNA is acting as a signaling molecule as the transcription of 
the lncRNA takes place at the specific time and place to integrate the developmental cues, interpret 
cellular context, or respond to diverse stimuli. This signifies that their expression is in response to 
specific transcriptional control mechanisms by the diverse cellular stimuli such as cellular stress and 
temperature.  After transcription, lncRNAs might be involved in other regulatory mechanism or they 
might also be byproduct of the transcription.  The signal lncRNAs can be used as a marker for the 
functionally significant biological event in the cell. [15] 
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2.2.2 Decoy 
 
The second archetype in the molecular mechanism of the lncRNA is Decoy.  After transcription, decoy 
lncRNAs bind and titrate away protein factors such as transcription factors, chromatin modifier and 
other regulatory factors from its target without exerting any additional function. Decoy lncRNAs 
“sponge” the protein factors leading to a broad change in the cellular transcriptome as it is shown in 
the figure 4 II. [15] 
 
2.2.3 Guide 
 
The third archetype of lncRNA is guide in which the lncRNA binds to the protein and directs the 
localization of the ribonucleoprotein complex to specific target. As a result the guide lncRNA can 
guide changes in gene expression either in cis (to its neighboring genes) or in trans (to the distance 
genes) that cannot be easily predicted by just the lncRNA sequence itself as it is illustrated in the 
figure 4 III.  [15] 
 
2.2.4 Scaffold 
 
Assembly of complex protein complexes can be supported by fourth archetype of lncRNAs, which 
serve as central platforms upon which relevant molecular components are assembled. The scaffold 
lncRNAs link factors together to form new functions. Some lncRNAs possesses different domains that 
bind distinct protein factors that altogether may impact transcriptional activation or repression. 
Figure 4 IV shows how scaffold works. [15] 
 
2.3 LncRNA identification 
 
The identification process of the lncRNA starts from obtaining all transcripts including ncRNAs and 
mRNAs. Then the next step is going to be classifying each transcripts based on the coding potential. 
After distinguishing the mRNA from the ncRNA, then lncRNA are from the other small ncRNAs. This 
can be achieved by both experimental and computational methods. 
 
Experimentally, the traditional microarray are designed to detect the protein coding transcripts or 
mRNA.  Therefore, there has to be other unbiased experimental methods, such as tilling array, serial 
analysis of gene expression (SAGE), high-throughput RNA sequencing (RNA-seq), RNA-
immunoprecipitation (RNA-IP) and Chromatin Signature-Based Approach, to identify of the lncRNAs 
from mRNAs. 
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Computationally, the lncRNAs can be identified in three ways. The first one is using ORF Length 
Strategy.  The second approach is sequence and secondary structure conservation strategy while the 
third approach is using the machine learning strategy. 
 
Figure 4. The molecular mechanisms of lncRNAs [15] 
 
 
2.3.1 Experimental methods 
 
2.3.1.1 Tilling array 
Tilling array is subtype of microarray in which cDNA is hybridized to the microarray slides carrying 
overlapping oligonucleotides that cover either specific chromosomal regions or a complete genome. 
It allows the analysis of global transcription from specific genomic regions and it was initially used 
for both identification and expression analysis of lncRNAs. [16] 
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2.3.1.2 Serial analysis of gene expression (SAGE) 
 
Serial analysis of gene expression (SAGE) is a technology capable of producing large number of short 
sequence tags identifying both known and unknown transcripts. It is based on the generation of short 
stretches of unbiased cDNA sequence SAGE tags by restriction enzymes.  SAGE tags are then 
concatenated before cloning and sequencing. [19] 
 
It has been used and proved to be an efficient approach in identification and analysis of lncRNAs. For 
example, Gibb et al. compiled 272 human serial analysis of gene expression (SAGE) libraries to 
delineate lncRNA transcription patterns across a broad spectrum of normal human tissues and 
cancers. [17] 
 
2.3.1.3 High-throughput RNA sequencing (RNA-seq) 
 
As the sequencing technology is advancing rapidly, RNA-seq or whole transcriptome shotgun 
sequencing experiment is becoming the mainstream technique in novel discovery of transcripts and 
gene expression analysis.  RNA-seq has advantage over the other techniques in that it is sensitive in 
detecting the less abundant transcripts. In addition to that it is also effective in identifying de novo 
splicing isoforms and novel ncRNAs. Figure 5 show the workflow of identification of the lncRNAs. 
[14] 
 
RNA-seq is the most widely used technique in identification of lncRNAs.  For example, Li et applied 
the RNA-seq experiment in the identification of lncRNAs during chicken muscle development. [20] In 
the other way, Prensner et al also used RNA-seq experiment to study lncRNAs in prostate cancer from 
102 prostate cancer tissues and cell lines. Based on the study, it has been concluded that lncRNAs 
may be used in cancer subtype classification. [21] 
 
2.3.1.4 RNA-immunoprecipitation (RNA-IP) 
 
RNA-IP is a technique that is used to identify lncRNAs, which are interacting with the specific protein 
molecule. The antibody of the protein is used to isolate the lncRNA-protein complexes, and then deep 
sequencing the cDNA library results in the sequences of lncRNA that has been interacting with the 
given protein. [14] 
 
2.3.1.5 Chromatin Signature-Based Approach 
 
Chromatin signature-based approach used the chromatin signatures to study the transcription of the 
lncRNA genes and others.  This chromatin signature includes H3K4me3, the marker of active 
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promoters, and H3K36me3, the marker of transcribed region.  Guttman et al. has used this approach 
in identifying 1600 large multiexonic lncRNAs regulated by the p53 and NFkB transcription factors. 
[22] 
 
Figure 5. The workflow in the identification of lncRNAs using RNA-seq [14] 
 
 
2.3.2 Computational Methods 
 
2.3.2.1 ORF Length Strategy 
 
It is known that the start and termination codon for lncRNA are distributed randomly. This implies 
that the ORF in lncRNAs are hardly any to find, if there exists, it is short in length, not more than 100 
codon. In this method, transcripts that lack the open reading frame (ORF) or have short ORF are 
computationally identified. [14] 
 
However, this method is not efficient way to identify lncRNAs from mRNAs as there are protein-
coding transcripts with shorter ORF and noncoding RNAs with ORF of longer ORFs.  To overcome 
this problem, Jia et al. utilized the comparative genomic approach in which they used the cDNA that 
have no homologous protein more than 30 amino acids across the mammalian genome are regarded 
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as lncRNAs. [23] As this approach is heavily dependent on the completeness of the database, the lack 
of the genomic annotation highly influences the result. [14] 
 
2.3.2.2 Sequence and secondary structure conservation strategy 
 
LncRNAs are generally less conserved as compared to the protein coding RNAs. Thus, they are 
subjected to mutation. The codon substitution frequency (CSF) is one of the criteria to measure 
mutation. Therefore, it could be used as the means to identify the lncRNAs.  For example, Guttman et 
al. used the CSF score as a means of calculating the coding potential for the RNA sequences and 
identified the lncRNAs from the coding RNAs. [24] In the other hand, Clamp et al. and Lin et al. 
combined the CSF with reading frame conservation (RFC) to come up with better way of identifying 
the lncRNAs from the mRNAs.  [25][26] PhyloCSF [28] is a tool that implement two phylogenetic 
models based on the intrinsic features of the sequence and sequence conservation to distinguish the 
coding and noncoding RNAs. [33] 
 
There are also other approaches that are engaged in identifying the lncRNAs from the mRNAs using 
the conservation of the RNA’s secondary structure. Tools that are implemented in such a way 
includes QRNA [29], RNAz[30] and EvoFOLD[31]. But, this approach has a major limitation in that 
the lncRNAs do not have common secondary structures. [14] 
 
2.3.2.3 Machine learning strategy 
 
There are a number of tools that has been developed to identify the lncRNA from the mRNA utilizing 
different machine learning techniques. For example, coding-non-coding (CONC) is a tool that has 
been developed using a support vector machine (SVM). It classifies transcripts according to features 
they would have if they were protein coding.  This features, such as peptide length, amino acid 
composition, predicted secondary structure content, predicted percentage of exposed residues, 
compositional entropy, number of homologs from database searches, and alignment entropy, are 
used to train the SVM model. [34][14] 
 
Another tool that has been developed using the machine learning approach is coding potential 
calculator (CPC). [35] CPC also uses SVM for modeling and extracting the sequence features and 
comparative genomic features to calculate the coding potential of the transcripts. [35] In the other 
hand, Lu et al. has also developed a tool using machine learning method that uses the GC contents, 
DNA conservation and expression information to identify the coding and noncoding transcripts in C. 
elegans genomes. [38] Table 1 summarizes the machine learning methods and the features used to 
train the models. 
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However, as different machine learning methods shown effectiveness in identifying lncRNAs, there 
are concerns that there are still exceptional cases. For example, some genes are bifunctional and 
exhibit both coding and non-coding isoforms such as in the case of steroid receptor RNA activator 
(SRA). [36] In the other hand, the transcriptability of RNAs might change during the course of 
evolution as Xist lncRNA evolved from protein coding gene. [37] 
 
Table 1. Machine learning methods for identification of lncRNAs [14] 
 
2.4 Function of lncRNA 
 
Recent studies have shown that lncRNAs have diverse cellular functions. Figure 6. Shows different 
functions that lncRNA is involved in. lncRNAs play a major role in different epigenetic regulations in 
a cell by recruitment of chromatin remodeling complex (CRC) to specific loci.  In this regard, Pandey 
et al. [39] showed that Kcnq1ot1, lncRNA found in KCNQ1 loci, is important for the bidirectional 
silencing of genes in Kcnq1 domain by interacting with chromatin, H3K9- and H3K27-specific histone 
methyltransferases G9a and PRC2 complex in a lineage-specific manner. In other study Nagano et al. 
[40], Air, which is another lncRNA, is responsible for allele specific transcriptional silencing of cis-
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linked Slc22a3, Slc22a2, and Igf2r genes in mouse placenta by interacting with the Slc22a3 promoter 
chromatin and the H3K9 histone methyltransferase G9a in placenta. 
 
 
Figure 6. Function of lncRNAs[43] 
 
The second cellular function of lncRNA is regulation of gene expression by interacting with protein 
partners in the biological process such as protein synthesis, imprinting (Kcnq1ot1, Air), cell cycle 
control (TERRA), alternative splicing (MALAT1), and chromatin structure regulation (DNMT3b, 
PANDA). MALAT-1 regulates alternative splicing through its interaction with the serine/arginine-
rich (SR) family of nuclear phosphoproteins, which are involved in the splicing machinery. Another 
lncRNAs such as Gas5 and p21 (lincRNA-p21) are involved in apoptosis and cell cycle control. [41] 
 
Thirdly, lncRNAs plays significant role in enhancer-regulating gene activation (eRNAs) in which they 
interact with distal genomic regions. The distal genomic region, such as enhancers, transmits 
transcriptional regulation instructions by interacting with lncRNAs. [42] 
 
Fourthly, lncRNAs has functional role in processing of small RNA molecules. lncRNAs are processed 
to yield small noncoding RNAs. They can also modulate how other small RNAs are processed. 
Therefore, lncRNAs can act as an interacting partner or precursor for the small RNAs. For example, 
microRNA (miRNA) are usually the result of sequential cleavage of lncRNAs. Figure 7A. Illustrates 
how lncRNAs are cleaved to yield two small ncRNAs. Figure 7B shows that how MALAT1 lncRNA 
transcript is processed to yield two small ncRNAs. The Piwi-interacting RNA (piRNAs) can also be 
produced by processing single lncRNA transcript. [43] 
 
Fifthly, lncRNAs serve as structural component. A number of RNA-binding proteins, including 
paraspeckle protein component 1 (PSPC1, also known as PSP1α) and NONO (also known as 
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p54/nrb), localize to paraspeckles.  paraspeckles is an irregularly shaped compartment of the cell in 
the nucleus’s interchromatin space. This dynamic structure can be altered in response to 
 
 
 
Figure 7. LncRNA processing to yield small ncRNA[43] 
 
cellular metabolic activity. They are transcription dependent. As the exact function of the 
paraspeckles not known, they are suggested to act as the storage site for nuclear-retained RNAs. The 
RNase A treatment of the paraspeckles result in the disruption of structural integrity of paraspeckles 
implying that lncRNAs can be a crucial components of the nuclear structure. [43] 
 
 
2.5 LncRNA and disease 
 
Studies show that the expression of lncRNAs is tissue specific. The majority of lncRNAs have brain-
specific expression patterns implying that the deregulation of lncRNAs have important role in the 
central nervous system (CNS) pathologies such as neurodevelopmental, neurodegenerative and 
neuroimmunological disorders, primary brain tumors and psychiatric diseases. The loss-of-function 
studies on mouse embryonic stem (ES) cell also showed that the knockdown of the lincRNA have 
significant role in the regulation of gene expression pattern in trans. This indicates that the lncRNAs 
play important role in the regulation of the diverse cellular processes such as stem cell pluripotency, 
development, cell growth and apoptosis, and cancer invasion and/or metastasis. [44] 
 
There is an increasing number of evidences that show the mutation and dysregulation of lncRNAs 
including the alteration of the primary and secondary structure together with the expression level of 
the lncRNAs and the RNA-binding protein associated with it lead to diverse human diseases ranging 
from neuronal to cancer diseases.[45] 
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The dysfunctionality of lncRNAs appears to be the cause for majority of complex human diseases 
such as leukaemia[143], colon cancer[144], prostate cancer[145], breast cancer[146], 
hepatocellular carcinoma[143],[147], psoriasis[148], ischaemic heart disease, [149],[150], 
Alzheimer's disease[151] and spinocerebellar ataxia type 8[152]. The following table summarizes 
the name of lncRNAs and their function in most frequent cancer types. 
 
Table 2.  LncRNAs in frequent cancer types [46] 
LncRNA Function Reference 
Prostate 
CBR3-AS1 Oncogene [49] 
CTBP1-AS Oncogene [50] 
GAS5 Tumor suppressor [51],[52] 
H19 Putative susceptibility and 
diagnostic marker 
[53],[54] 
MALAT1 Putative marker [55] 
PCA3 Diagnostic marker [56],[57] 
PCAT1 Putative marker and oncogene [58] 
PCGEM1 high-risk pridictive marker and 
oncogene 
[59],[60],[61],[62],[63],[64],[65] 
PRNCR1 Oncogene [66],[67] 
PTENP1 Oncogene, tumor suppressor [68],[69] 
ucRNAs Putative oncogene [70] 
XIST Diagnostic and prognostic 
marker 
[71],[72] 
Breast 
ANRIL Tumor suppression [73] 
BC040587 Prognostic biomarker [74] 
BCAR4 Oncogene [75] 
BCYRN1 Prognostic biomarker [76] 
DSCAM-AS1 Involved in malignant 
progression 
[77] 
GAS5 Tumor suppression [78] 
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H19 Oncogenic, involved in 
imprinting 
[79] 
HOTAIR Prognostic marker of metastasis [80] 
LincRNA-BC4 Associated with advanced 
diseases 
[81] 
LincRNA-BC5 associated with advanced 
diseases 
[81] 
LSINCT5 Proliferation [82] 
Loc554202 proliferation and cell migration [83] 
MALAT1 Splicing and metastasis [79] 
MEG3 Suppression of growth [84] 
MIR31HG Epigenetics [85] 
PINC Cell survival and progression [86] 
PVT1 Inhibition of apoptosis [87] 
SRA1 Co-activator of estrogen receptor 
alpha 
[87] 
XIST Epigenetics [89] 
ZNFX1-AS1 Tumor suppressor [90] 
Lung 
CCAT2 Invasion [91] 
HOTAIR Proliferation and invasion [92] 
LincRNA-P21 Mediated gene repression [93] 
LincRNA-MVIH Proliferation and invasion [94] 
MALAT1 Metastasis [95] 
MEG3 Suppression of growth [84] 
MINA Oncogene [96] 
TUG1 Suppression of cell proliferation [97] 
Colorectal 
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CCAT1 Diagnostic marker and involved 
in proliferation and invasion 
[98],[99] 
CRNDE Diagnostic marker [100] 
HULC Liver metastasis [101] 
HOTAIR Metastasis [102] 
KCNQ1OT Epigenetic modifier [103] 
LincRNA-P21 Suppression of P53 target gene 
and enhances sensitivity to 
radiotherapy 
[104],[105] 
lnc-LET1 Hypoxia mediated metastasis via 
HDAC3 
[106] 
MALAT1 Metastasis [107] 
SNGH16 Cell migration and invasion [108] 
Melanoma 
ANRIL Scaffold of the chromatin 
modifying complex 
[109] 
BANCR Cell migration [110] 
C9orf14 candidate tumor suppressor [111] 
SPRY4-IT1 Modulates apoptosis and 
invasion 
[112] 
Bladder 
Linc-UBC1 Negative prognostic factor [113] 
H19 Recurrent marker [114] 
MALAT1 Mediator of TGF-B-induced 
epithelial mesenchymal 
transition 
[115] 
MEG3 Possible tumor suppressor [116] 
SNHG16 Proliferation, invasion and 
affects sensitivity of 
chemotherapy 
[117] 
TUG1 Proliferation [118] 
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UCA1 Cell proliferation, migration and 
chemoresistance 
[119] and [120] 
Non-Hodgkin lymphoma 
BIC Up-regulation in B-cell 
lymphomas 
[121] 
Kidney (renal cell and renal pelvis) cancer 
GAS5 Tumor suppressor [122] 
H19 Tumor suppressor [123] 
HIF1A-AS1 Up-regulated in cancer [124] 
HIF1A-AS2 UP-regulated in cancer [124] 
KCNQ1OT1 Oncogene [125] 
MALAT1 Tumor progression and poor 
prognosis 
[126] 
MEG3 Tumor suppressor [127] 
Thyroid 
AK023948 Down-regulated in thyroid 
carcinoma 
[128] 
NAMA Activated by BRAF 
mutation,contributes to cell 
proliferation and activates 
autophagy 
[129] 
PTCSC3 Down-regulated in papillary 
thyroid carcinoma 
[130] 
Endometrial 
CASC2 Potential tumor suppressor [131] 
HOTAIR Proliferation and invasion [132] 
MALAT1 Up-regulated [133] 
Leukemia (all types) 
ANRIL Silencing of CDKN2B [134] 
DLEU1 Tumor suppressor, harbors mir-
15-a and mir-16-1 
[135] 
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DLEU2 Tumor suppressor, harbors mir-
15-a and mir-16-1 
[136] 
MEG3 Tumor suppressor methylated in 
acute myeloid leukemia 
[137] 
MIR155HG Direct NF-κB target gene [138] 
TCL6 Involved in leukemogenesis [139] 
WT1 AS,Epigenetic and splicing 
defects 
[140] 
Pancreatic 
DAPK High expression in metastatic 
disease 
[141] 
HOTAIR Predictive of metastasis and 
disease progression 
[102] 
MALAT1 Splicing,metastasis [79] 
MAP3K14 High expression in metastatic 
disease 
[141] 
PPP3CB High expression in metastatic 
disease 
[141] 
PVT1 Drug sensitivity regulation [142] 
 
 
 
Recent studies show that some lncRNAs are involved in mediating invasion and metastasis in the 
cancer cells by altering the gene expression pattern epigenetically. Such lncRNAs are identified to be 
polycomb repressive complexes (PRC) protein dependent in transcriptional control. PRCs are the 
polycomb group (PcG) proteins that function in multiprotein complex. [47] PcG proteins play major 
role in repressing the promoter of the genes that are crucial in the cell fate determination and 
embryonic development. In cancer, the PcG target genes are frequently silenced epigenetically by 
DNA methylation due to the high level of expression of PcG proteins in the cancer cell. HOTAIR, PCAT-
1 and MALAT1 are lncRNAs that are involved in the PRC dependent transcriptional control that their 
overexpression induces metastasis and invasion in different cancer cells. [47] 
2.5.1 HOTAIR (HOX transcript antisense intergenic RNA) 
 
The lncRNA HOTAIR is located at the 12th chromosome HOXC locus (12q13.13) and it regulates the 
expression of HOXD genes at chromosome 2 by binding to PRC2 in trans.  It induces the epigenetic 
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silencing of several tumor suppressor genes at HOXC loci by metelation.   Gupta et al. [153] revealed 
the important role of HOTAIR in breast cancer metastasis. Additionally, the high level expression of 
the HOTAIR in primary breast tumor is a powerful indicator of metastasis and mortality. Conversely, 
the low level of expression of HOTAIR inhibits cancer invasiveness in cells with high excessive PRC2 
activity.[153][47] HOTAIR is involved in one or other way in the following cancer types: Lung, breast, 
colorectal, esophageal, laryngeal, nasopharyngeal, hepatocellular, gastric, pancreatic carcinoma, non-
small cell lung cancer, mesenchymal glioma cancers. 
2.5.2 PCAT-1 (prostate cancer-associated ncRNA transcripts-1) 
 
The PCAT-1 lncRNA is located at 8q24 which is considered as a “gene desert” loci, around the well-
studied SNP associated with prostate cancer risk, nearly 725 kb upstream of the c-MYC oncogene.  
Recent studies Prensner et al. [154] show that the PCAT-1 is associated with metastasis and can 
promote the cell proliferation in prostate cancer by repressing the PRC2 complex. However, further 
studies is still needed in order to well explain the regulatory mechanism of PCAT-1. [154] 
2.5.3 MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) 
 
MALAT1 is lncRNA later referred to as NEAT2 (nuclear-enriched abundant transcript 2) that act as 
the prognostic marker of metastasis and patient survival in non-small cell lung cancer. [155][156] As 
MALAT1 is the most abundant in human cell types and highly conserved across several species, the 
deeper the study of this lncRNA is expected to reveal the functional mechanism and importance of 
the lncRNAs. MALAT1 is upregulated in lung, breast, prostate, colon and liver cancers.[46] The 
molecular mechanism of MALAT1 is identified as the regulator of the alternative splicing for certain 
genes[158], the genetic regulator of the metastasis-associated genes in lung cancer and activator of 
gene expression in mediating the assembly of coactivator complexes by binding to the unmethylated 
polycomb 2 (Pc2) which is a component of the polycomb repressive complex 2(PRC2).[157] 
 
Many of the LncRNAs are recently being associated with p53 signaling pathway. Huarte et al.[158] 
has showed significant number of lncRNAs are a key constituent of the p53-dependent 
transcriptional pathways. For example, MALAT1, H19 and CCAT2 lncRNAs are involved in the Wnt/β-
catenin pathway. [47] 
2.5.4 H19 
 
The H19 lncRNA, which is imprinted and maternally expressed at 11p15.5 in the genome, near the 
insulin like growth factor 2(IGF2) gene, has crucial role in genomic imprinting during the cellular 
growth and development. H19 is expressed marginally in nearly all normal adult tissues while the 
aberrant expression is observed in several cancer types including breast, hepatocellular, colon, 
bladder and esophageal cancers. It is also indicated that H19 plays important roles in gastric cancer. 
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H19 is involved in the down regulation of RB tumor suppressor gene in colorectal cancer by acting 
as a precursor for miRNA-675. [46][47] 
2.5.5 GAS5 (The Growth Arrest Specific 5) 
 
GAS5 at 1q25 is important player in mammalian apoptosis and cell growth. It binds to the receptors 
in a cell to inhibit the association of the receptors by blocking their binding domain. As a result several 
genes including cellular inhibitor of apoptosis 2 gene are suppressed and there will be a reduced 
cellular metabolism leading to cellular death. In both prostate and breast cancers GAS5 induces 
apoptosis directly or indirectly. [46] GAS5 has significantly reduced expression level in breast cancer 
cell as compared to the normal.[78] It also act as a tumor suppressor in renal cell carcinoma.[160] 
Studies also show that the decreased expression of GAS5 implicates that poor progenesis in cervical 
cancer. [161] 
2.6 LncRNAs in diagnosis and therapy of cancer 
As cancer is multifactorial and multistep disease, the need to have molecular malignancy biomarker 
is immense in cancer patient management. In the past, several biomarkers in several cancer types 
are discovered and validated, but recently, the lncRNAs are being introduced as a potential biomarker 
in the diagnostics and prognostics of different cancer types via both oncogenic and tumor-
suppressive pathways. For example, the increased level of expression of HOTAIR is associated with 
metastasis in breast cancer. In addition, the expression of HOTAIR is correlated with metastasis in 
colorectal and many other malignant neoplasms in liver, stomach, nasopharynx, esophagus, and skin. 
[47] 
In addition to the diagnostic potential of lncRNAs, studies also has shown lncRNAs can be potential 
therapeutic target.  As the inhibition of some lncRNAs, such as MALAT1, are involved in metastasis 
and poor progenesis in non-small lung cancer, and the inhibition of MALAT1 does not affect the 
normal cell, there is a big potential of using such lncRNAs as a therapeutic target in metastatic 
cancers. [155][162] In recent study, Wheeler et al. [163], showed that the abolition of MALAT1 using 
gene therapy in vivo has a significant potential of curing a metastatic cancers. Other study, Ren S et 
al. [164], also showed that MALAT1 is involved in the maintenance of prostate tumorigenicity and be 
a potential therapeutic target for castration-resistant prostate cancer in nude mice by delayed tumor 
growth and reduced metastasis of the prostate cancer cells. 
2.7 lncRNA databases 
 
The accessibility of lncRNAs in public dataset is becoming more realistic in recent years. There are a 
number of lncRNA databases, with different data coverage and quality, are developed to give services 
via web interface.  The number of lncRNAs stored in the existing databases is different based on the 
source of transcripts. The lncRNAs stored in the databases might be collected in one of the following 
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means:  literature, computational predictions, or primary data repositories such as informations 
from GENCODE project. But Functional lncRNA Database and lncRNADisease databases are mairly 
rely on the manually curated, literature-extracted annotations. Most of the lncRNA databases contain 
human and mouse lncRNAs while LncRNAdb and Noncode v4.0 databases covers large number of 
species’ lncRNAs ranging from yeast to plants.[165] Table 3 summarizes the lncRNA databases. 
 
NONCODEv4 is one of the largest databases that hosts around 210 831 lncRNAs transcripts for 
human and mouse. It gives the graphical expression profile of lncRNA genes based on public RNA-
seq data and predicts their functionality for both human and mouse.[166] CHIPBase, DIANA-LncBase, 
lncRNAdb, Noncode v3.0, and lncRNome databases provide cell or tissue specificity of the lncRNAs, 
but only lncRNAdb and Noncode v3.0 designate the cellular localization of the lncRNAs.[165] 
 
DIANA-LncBase is another lncRNA database with the largest number of experimentally verified, 
about 5000, and computationally predicted, about 10 million, microRNA targets on the lncRNAs.  It 
provides the detail information on miRNA-lncRNA interaction with external links, graphic plots of 
transcripts’ genomic location, representation of the binding sites, lncRNA tissue expression as well 
as MREs conservation and prediction scores. [168] 
 
Some lncRNA databases such as DIANA-lncBase, lncRNAdb, Noncode v3.0, and lncRNome describe 
lncRNAs based on the validated and putative biological functional annotations. Functional lncRNA 
database exclusively contains the lncRNA-associated diseases that are experimentally validated 
while DIANA-lncBase, lncRNAdb, lncRNADisease, Noncode v3.0, and lncRNome provide putative or 
validated associations between lncRNAs and diseases. [165] 
 
Table 3. List of lncRNA databases 
Database Web access link Description Reference 
lncRNAdb http://www.lncrnadb.org/ 
 
Contain comprehensive list of 
lncRNAs in eukaryotes, and 
mRNAs with regulatory roles 
[168] 
NONCODEv4 http://noncode.org/ 
 
Integrative annotation of 
noncoding RNA(210 831 
lncRNAs) 
[166] 
LNCipedia http://www.lncipedia.org/ 
 
offers 21 488 Annotated human 
lncRNA transcripts with 
secondary structure information, 
protein coding potential, and 
microRNA binding sites 
[169] 
The functional 
LncRNA database 
http://www.valadkhanlab.org/dat
abase 
Contains studied lncRNAs 
manually culled from the 
literature along with a parallel 
[170] 
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database containing all annotated 
protein-coding human RNAs 
ChIPBase 
 
http://deepbase.sysu.edu.cn/chip
base/ 
Decods the transcriptional 
regulation of microRNA and 
lncRNA genes from ChIP-Seq data 
 
[171] 
DIANA-LncBase 
 
www.microrna.gr/LncBase Experimentally verified and 
computationally predicted 
microRNA targets on long non-
coding RNAs 
 
[172] 
LncRNADisease 
 
http://cmbi.bjmu.edu.cn/lncrnadis
ease 
A database for long-non-coding 
RNA-associated diseases 
 
[173] 
LncRNA2Target 
 
http://www.lncrna2target.org/ a database for differentially 
expressed genes after lncRNA 
knockdown or overexpression 
 
[174] 
lncRNASNP 
 
http://bioinfo.life.hust.edu.cn/lnc
RNASNP/ 
a database of SNPs in lncRNAs and 
their potential functions 
 
[175] 
LncRNAWiki http://lncrna.big.ac.cn/index.php/
Main_Page 
 
Community Curated Database For 
LncRNA 
 
[176] 
lncRNome 
 
http://genome.igib.res.in/lncRNo
me 
A comprehensive knowledgebase 
of human long noncoding RNAs 
 
[177] 
PLncDB http://chualab.rockefeller.edu/gbr
owse2/homepage.html 
Plant Long noncoding RNA 
Database 
 
[178] 
StarBase v2.0 http://starbase.sysu.edu.cn/panCa
ncer.php 
Decods Pan-Cancer and 
Interaction Networks of lncRNAs 
from TCGA 14 cancer types 
 
[179] 
ALDB http://res.xaut.edu.cn/aldb/index.
jsp 
 
Comprehensive database with a 
focus on the domestic-animal 
lncRNAs 
[180] 
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2.8 lncRNA functional prediction 
 
Unlike the protein coding genes, it is difficult to predict the functionality of lncRNA based on their 
sequence motifs and secondary structures as lncRNAs are not conserved and does not have 
conserved sequence motifs. As lncRNAs are involved in regulation of cellular activities by interacting 
with other molecules, recent studies has concentrated their attention towards exploring the relation 
between lncRNAs and proteins, protein coding genes and miRNAs. In general, there are three 
approaches that has been deployed for the computational functional prediction of lncRNAs such as 
Comparative genomic approach, co-expression with coding genes approach and interaction with 
miRNAs and proteins approach. [181][14] 
      
3.8.1 Comparative genomic approach 
 
Though lncRNAs are not conserved across different species, Amit et al. [182] identified 78 lncRNAs 
that are conserved both in human and mouse and found 70 of them are located within or close to 
1000nt distance from the coding genes that are also conserved in both human and mouse. This 
implies that lncRNAs that are in a close proximity with the coding genes might have functional 
relationship. But this approach lacks efficiency because of poor conservation of lncRNAs and it cannot 
be applied at the genomic scale.  [14] 
 
2.8.2 Co-expression with coding gene approach 
 
This approach is based on the assumption that the lncRNA that is regulating certain biological process 
might be co-expressed with the protein coding genes that are involved in same biological process. 
[14] Hao et al. [184] utilized this assumption to predict functionality of lncRNAs in carcinogenesis of 
esophageal taking samples from four patients with Primary ESCC tumors and adjacent non-
neoplastic tissues conducted the differential expression analysis followed by the co-expression 
analysis using limma & RedeR R packages respectively.  Then, the experimental quantitative real time 
polymerase chain reaction with small interfering RNA-mediated knockdown and apoptosis & 
invasion assays are applied in vitro to predict the onco-lncRNAs. 
 
Yun Xiao et al. [183] applied a bayesian network model to identify the co-expression relationship 
between the lncRNAs and protein coding genes.  Using 58 prostate cancer samples, Yun Xiao et al. 
identified and constructed the expression profiles of both lncRNAs and protein coding genes.  Then, 
the bayesian network method is applied to construct the regulatory network based on the 
relationship between the lncRNA and protein coding genes. Finally, each protein coding genes that 
are linked to the lncRNAs from the regulatory network is mapped to the protein-protein interaction 
network and subsequently the functionality of the lncRNAs is predicted.   
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Liao et al. [185] also applied the coding-noncoding (CNC) gene co-expression network in two ways 
to predict the function of the lncRNAs: the hub-based and the network-module-based approaches. In 
hub-based network model, the function of the lncRNA is predicted based on the functional 
enrichment of its neighboring genes while network-module-based approach utilizes the Markov 
cluster algorithm (MCL) to identify the co-expressed functional module in the CNC network. [185] 
 
2.8.3 Protein & miRNA Interaction approach   
 
It is speculated that lncRNA is involved in the regulatory network in synergy with miRNA and 
proteins. Some miRNA and proteins bind to lncRNA to carry out their activity in the cell. Therefore, 
identifying those miRNAs and proteins that interact with the lncRNA is expected to reveal the 
possible function of the lncRNAs. With this regard, Jeggari et al. [187] developed an algorithm called 
“miRcode” that can predict the possible miRNA binding site on lncRNAs based on their seed 
complementarity and evolutionary conservation. Jeggari et al. used the algorithm to build the 
genome-wide network of validated miRNA mediated interaction to reveal the previously unknown 
mediatory role of lncRNA and miRNA. 
 
Bellucci et al. [188] on the other hand came up with a method called “catRAPID” that can correlate 
the lncRNAs with proteins based on calculating their interaction potential using physicochemical 
characteristics such as secondary structure, hydrogen bonding, van der Waals, and others. 
 
 
Figure 8 the snapshot of the catRAPID web service for protein-RNA interaction 
 
The RPISeq [200][201] is another web based  tool that uses only sequence information to train the 
support vector machine(SVM) and random forest(RF) machine learning algorithms. 
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Figure 9. The snapshot of the RPISeq web service for protein-RNA interaction 
 
 
However, applying this interaction-based approach in miRNAs and proteins is only limited to specific 
lncRNAs as mechanism of interaction for the lncRNAs with other bimolecular elements are still 
unclear. On the top of that, there are small number of lncRNAs whose functions are well studied 
making the computational functional prediction difficult in such a way that validation and 
optimization of computational algorithms are unattainable. [14] 
2.9 RNA-seq data analysis 
 
RNA sequencing technology is one of the high-throughput sequencing technique getting popularity 
in transcriptome profiling using deep sequencing approach. The overall work flow of RNA-seq 
protocol is shown in the figure below.  
 
 
Figure 10. The work flow of RNA-seq sequencing [206]  
 
The first step in RNA-seq work flow is to identify the research questions to be addressed by setting 
up experimental design such as identifying expressed transcript, identifying boundary exon/intron 
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junctions and transcription start site (TSS) or poly-A sites. The research question at hand can also 
be to identify the difference in expression among two or more sample groups.  The next step in the 
work flow is RNA preparation by isolating and purifying the RNA samples. The isolated RNAs are 
converted to cDNA and then the sequencing adapter is attached to each of the cDNAs as shown in 
the figure 11. This step is known as a library preparation step and the cDNAs with sequencing 
adapter are referred as a libraries.   
 
 
 Figure 11. RNA-seq experiment  
 
The next step in the RNA-seq work flow is to fragment the cDNA libraries and sequence it using 
sequencing platforms such as Illumina or SOLiD sequencer. The reads that are sequenced by the 
sequencer are of three types: exonic read, junction read and poly-A end reads. Finally, by aligning 
the reads with reference genome and quantify the expression of the transcript by counting  the 
number of reads mapped to certain region in the genome, one can undergoing through different 
analysis technique to address the targeted research questions.  
2.9.1 Normalization  
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Before directly proceeding with applying different statistical analysis methods to address the 
research question, the expression raw count data has to be comparable across features (genes and 
transcripts) and across the different libraries or samples. It also has to be in human friendly scale or 
magnitude. The process of preparing the row count data in such a way is known as normalization. 
 
There are a number of techniques that are proposed to perform normalization for RNA-seq data such 
as total Count (TC), upper quartile (UQ), Median (Med), DESeq2, Trimmed Mean of M values (TMM), 
Quantile (Q) and Reads per Kilobase per Million mapped reads (RPKM) normalization. [187]  
 Total count (TC): Gene counts are divided by the total number of mapped reads (or library 
size) associated with their lane and multiplied by the mean total count across all the samples 
of the dataset. 
 Upper Quartile (UQ): Very similar in principle to TC, the total counts are replaced by the 
upper quartile of counts different from 0 in the computation of the normalization factors. 
 Median (Med): Also similar to TC, the total counts are replaced by the median counts 
different from 0 in the computation of the normalization factors. 
 DESeq: This normalization method is included in the DESeq Bioconductor package (version 
1.6.0) and is based on the hypothesis that most genes are not DE. 
 Trimmed Mean of M-values (TMM): This normalization method is implemented in the 
edgeR Bioconductor package (version 2.4.0). It is also based on the hypothesis that most 
genes are not DE. 
 Quantile (Q): First proposed in the context of microarray data, this normalization method 
consists in matching distributions of gene counts across lanes. 
 Reads Per Kilobase per Million mapped reads (RPKM): This approach was initially 
introduced to facilitate comparisons between genes within a sample and combines between- 
and within-sample normalization. 
 
As different libraries are sequenced with different depth, DEesq2 uses statistical model to model the 
offsets and it makes sure that the parameters are comparable. In normalizing raw count data, DEseq2 
defines virtual reference sample by taking the median of each gene value across sample and 
computes the size factor as the median of the ratio of each sample to reference sample. Thus, dividing 
each column of the count table with the corresponding size factor should yield the normalized count 
value that can be scaled for interpretation. [187]  
2.9.2 Deferential expression analysis 
 
The expression or abundance of transcript in a given target sample can be inferred by examining 
the probability of the randomly drown read from millions of reads in the library uniquely map to 
the target. This probability distribution can be statistically modeled by discrete distribution model, 
continuous distribution model or nonparametric distribution model. In differential expression 
analysis, having the library of two samples A & B, if the probability of randomly drown read  from 
library A mapping to the target transcript is higher than that of the read that is randomly drown 
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from library B, then the target transcript is said to be differently expressed among the two library 
samples.   
 
In discrete distribution model, randomly drown reads can be modeled in person’s probability 
distribution. However, in RNA-seq data the variance of the probabilities among the individuals in 
the library is significantly higher than that of mean. As the person’s distribution assumes equal 
variance and mean, modeling RNA-seq data with person’s distribution will lead to “overdispersed” 
fit. This shortcoming of overdespersion in the person’s distribution modeling can be improved by 
adding additional desperation parameter to adopt another model called negative binomial (NB) 
distribution model. There are several R packages that implement the negative binomial models 
analyzing the deferential expression such as edgeR and DESeq.     
 
In the other way, normalizing and transforming RNA-seq read count values can be considered as a 
continuous distribution variable. If this continuous distribution is approximately normal, then it 
can be used to infer the differential expression among two groups using the continuous distribution 
models such as t-test.   
The nonparametric model method in analyzing the differential expression is employed if the real 
data does not conform any specific assumptions. In this approach the rank based test statistics such 
as Mann-Whitney is calculated for analyzing the differential expression among two sample groups. 
Taking the log ratio among the top and the lowest quartile of sample expression can also be used in 
the differential analysis among unknown samples.  
2.9.3 Gene list enrichment analysis 
 
By performing gene list enrichment analysis, one is identifying whether those genes list of interest 
overlap in certain gene lists from the database that are known for certain biological pathways, 
ontologies and other biological information that are intended to be revealed more than expected by 
chance. 
 
The team more than expected by chance signifies that the comparison between the two genes list 
have to have statistical certainty of enrichment. This can be achieved by utilizing different statistical 
approaches such as: 
 
✓ Fisher’s exact test 
✓ Hypergeometric test 
✓ Chi‐squared test 
✓ Z test 
✓ Kolmogorov‐Smirnov test 
✓ Permutation test 
 
In this particular project the gene lists of pathway from KEGG, the gene lists of the gene ontologies 
from GO database, gene lists that share motifs for miRNA and transcription factor proteins are 
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downloaded from MSigDB database and the Fisher’s exact test is used to statistically test the 
enrichment of the genes list of interest with corresponding gene lists from the database. 
 
Fisher’s exact test is a statistical testing method that is applied on contingency table. Contingency 
table in statistics is a table that contains the multivariate frequency distributions of variables. In the 
case of enrichment analysis the contingency table looks table 6. 
 
Table 6. The contingency table for gene list enrichment analysis 
 The number of all genes in the gene 
lists biologically related genes from 
database 
 
Yes No 
The number of top DE 
genes in gene lists from 
database 
Yes a b a+b 
No c d c+d 
 a+c b+d N=a+b+c+d 
 
Given the above contingency table for the datasets in the analysis, the null hypothesis for the above 
contingency table will be the number of overlapped genes from the top differently expressed gene 
with the one in the database are overlapped by chance. The p-value of significance is calculated from 
the above contingency table as: 
 
  
𝑃 − 𝑣𝑎𝑙𝑢𝑒 =
(𝑎 + 𝑏)! + (𝑏 + 𝑑)! + (𝑎 + 𝑐)! + (𝑐 + 𝑑)!
𝑁!. 𝑎!. 𝑏!. 𝑐!. 𝑑!
 
 
 Therefore, with Fisher’s exact statistical testing it can be determined whether the number of 
overlapped genes are significant to say the top differently expressed genes are enriched in certain 
biological gene ontology, pathways and other biological activities. 
2.10 Co-expression analysis methods 
The co-expression of two expression values from different data type can be analyzed using either 
Pearson’s correlation or mutual information as a measure of association. 
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 2.10.1 Correlation  
 
Correlation is a measure of how well the two data are related. Pearson Product Moment Correlation 
(PPMC) shows the linear relationship between the two sets of data. The Pearson correlation 
coefficient(r), which ranges from -1 to 1, is a measure of similarity between the dataset.  -1 means 
the two datasets are highly negatively correlated, +1 means the two datasets are highly positively 
correlated and 0 means there is no linear correlation between the two datasets.  Mathematical 
expression for the Pearson’s correlation coefficient is given by: 
 
  
𝑟 =
𝛴𝑋𝑌 −
(𝛴𝑋)(𝛴𝑌)
𝑛
√(𝛴𝑋2 −
(𝛴𝑋)2
𝑛 ) (𝛴𝑌
2 −
(𝛴𝑌)2
𝑛 )
 
where: 
𝑟 is the correlation coefficient 
𝑋 and 𝑌 are datasets and 
𝑛 is the number of data in the dataset 
 
 2.10.2 Mutual information  
 
If the dataset are not linear, applying the Pearson’s correlation might not lead to the ultimate 
solutions. In this case, applying the information theoretic based mutual information approach of a 
measure of association between the two datasets might be crucial. In information theory, information 
contained in variable can be quantified as “entropy”.  Given that random discrete variable X, the 
entropy is given by: 
 
  
𝐻(𝑋) = −𝛴𝑝(𝑥)𝑙𝑜𝑔𝑏𝑝(𝑥) 
 where: 
 𝐻(𝑋) is entropy of the discrete variable X, 
  𝑝(𝑥) is the probability of the single discrete element from variable X 
 
Depending on the use of logarithmic base, the unit of entropy varies. For example, if the base used in 
the logarithmic calculation is 2, the unit will be “bit”. If base used is Euler’s number e, the unit will be 
“nat”, and “dit” for the base 10 calculations. 
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Pairwise mutual information is a measure of shared information between the two random variables. 
Given two random discrete variables X & Y their mutual information can be given as: 
 
  
𝐼(𝑋, 𝑌) = 𝐻(𝑋) + 𝐻(𝑌) − 𝐻(𝑋, 𝑌) 
 Where; 
𝐼(𝑋, 𝑌) is a the pairwise mutual information of random variable X and Y, 
  𝐻(𝑋) entropy of random variable X, 
  𝐻(𝑌) is entropy of random variable Y and 
  𝐻(𝑋, 𝑌)is the joint entropy of the random variable X and Y 
 
Joint entropy, 𝐻 (𝑋, 𝑌) is the entropy of joint probability distributions of random variables X and Y.  
Mathematically the joint entropy of two random variables X and Y is given by: 
 
  
𝐻(𝑋, 𝑌) = − ∑ ∑ 𝑝(𝑥, 𝑦) log 𝑝(𝑥, 𝑦)
𝑛
𝑦𝜀𝑌
𝑛
𝑥𝜀𝑋
 
Where: 
𝐻(𝑋, 𝑌) is a joint entropy between two discrete variables X and  Y 
 
𝑝(𝑥, 𝑦) is a joint probability distribution of dataset x and y 
 
𝑝(𝑥) and 𝑝(𝑦)are  factorized marginal distribution of dataset x and y 
 
 
There are several algorithms that utilizes the mutual information as a measure of association 
between two dataset. For example, Algorithm for the Reconstruction of Accurate Cellular Networks 
(ARCENE), the context likelihood of relatedness (CLR), maximum relevance minimum redundancy 
network (MRNet) and network deconvolution algorithm use  mutual information as a measure of 
association.  
 
ARCENE algorithm is widely used in inferring the gene regulatory network and it is implemented in 
finding out the association between the genes, miRNAs and non-mRNA transcripts of this project to 
identify the association among them. There are three steps involved in association inference based 
on the ARACNE algorithm. The first one is pairwise mutual information calculation. The second step 
is based on significance threshold, it builds a graph of significant pairwise mutual information. 
Finally, it remove indirect connections from the network based on the violation of data processing 
inequality (DPI) principles. 
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According to the information theory, the data processing inequality (DPI) principles states that if 
there are three points A, B, C connected each where B is in the middle, then MI(A, B) >MI(A,C) & 
MI(B,C)>MI(A,C). Any connection that violates this principle, is indirect connection and removed 
from the network. 
2.11 Sequence based analysis 
 3.11.1 Interaction Motif scanning  
There are several approaches in figuring out the interactions between the DNA or RNA and proteins. 
These includes combinatorial approaches, using hamming distance, and probabilistic approaches 
such as position weight matrix (PWM) model and hidden markov model (HMM). PWM is widely used 
model in computational motif scanning.  
 
 
Figure 12.  From parallel alignment to PWM [188] 
 
The implementation of PWM algorithm begins with the parallel-aligned sets of binding sites with the 
length of m and the background distribution of q as it is shown in figure 12. The parallel-aligned sets 
of binding sites will be transformed into the position frequency matrix: 
 
𝑁𝑖𝑗= A   9    11  49  51  0 1   1   4 
C  19    3  0  0  0  45 25 16 
G  5    1  2  0 17 0 4 21 
T  18    36  0  0 34 5 21 10 
 
The second step is to add the pseudocount to each of the value in the position frequency matrix. This 
substitutes the zero count position with comparably smaller number, as it will result in zero 
probability in calculating the position probability matrix.  
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The third step in calculating the PWM is to transform the position frequency matrix from step two to 
the position probability matrix.  The position probability matrix is calculated by normalizing the 
individual frequency value from the position frequency matrix by the sum of column frequency value 
at particular position and the product of scaling parameter β and the background distribution q. 
mathematically, the position probability matrix is given by:   
  
𝑓𝑖𝑗 =
𝑁𝑖𝑗
∑ 𝑁𝑖𝑗
𝑛
𝑖=0 + 𝛴𝛽𝑞
 
 
The forth and the final step in calculating the PWM is to change the position probability matrix into 
the weighted position matrix by taking the logarithmic 2 ratio between the signal and the background 
frequencies as it is illustrated in the figure 12. Once the PWM is constructed, there need to be a score 
for each motif scan against the certain DNA sequence S with sequence length of L. The PWM score of 
the sequence S given the PWM is given by: 
𝑃𝑊𝑀𝑠𝑐𝑜𝑟𝑒(𝑆/𝑃𝑊𝑀) = ∑ 𝑃𝑊𝑀𝑠𝑖
𝑛
𝑖=0
 
 
Where, 𝑆  is the DNA sequence to be scanned for binding motif 
 𝑛 is the length of the motif to be scanned 
 𝑃𝑊𝑀 is the Position weight matrix   
𝑃𝑊𝑀𝑠𝑐𝑜𝑟𝑒(𝑆/𝑃𝑊𝑀) is the position weight matrix score for sequence S given PWM 
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3 OBJECTIVES  
 
In order to implement different approaches towards the functional prediction of the long non coding 
RNAs, publicly available human glioblastoma multiforme (GBM) for 169 samples are used from the 
Cancer Genome Atlas (TCGA) glioblastoma project (Brennan et al. 2013). Based on the result from a 
novel gene and transcript identification algorithm, Novellette [204], which is RNA-seq analysis 
pipeline for gene and transcript identification, it has been identified that there exist about 53 novel 
lincRNA transcripts from 169 human glioblastoma multiforme (GBM) samples. Nothing is known 
about these novel lincRNA transcripts. Therefore, there is a need to predict the functions of those 
lincRNA computationally. 
 
The goals of this project are: 
  
 To analyze the differential gene expression across the 169 human GBM samples 
 To analyze the differential novel transcript expressions across the GBM samples 
 To analyze differential miRNA expressions across GBM samples 
 To analyze the GO and pathway enrichment analysis with highly differently expressed 
genes 
 To identify the co-expressing novel lincRNAs with the well-studied genes 
 To identify the co-expressing novel lincRNA with known miRNAs 
 To apply motif scanning methods to figure out the interactions between top 
differently expressed genes and proteins 
 To apply motif scanning methods to figure out the interaction between the novel 
lincRNAs and proteins 
 To Identify the common proteins binding to both the top differently expressed gene 
and novel lincRNAs 
 To identify the RNA-RNA interaction between the top differently expressed miRNAs 
and novel lincRNAs  
 To predict the function of the novel lincRNAs by integrating the expression and 
interaction based analysis.   
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4 MATERIALS AND METHODS  
 
The functional prediction of the lncRNAs is carried out in combination with different approaches. The 
dataset used for this are the gene expression data, the novel transcript expression data and miRNA 
expression data for the glioblastoma multiforme from the TCGA samples. The primary stage of the 
analysis is identifying the gene of interest by applying quartile based differential gene expression 
analysis. Then, the gene list enrichment analysis for Gene ontology and pathway is performed to 
make sure that the genes of interest are related to glioblastoma. 
 
The first part of the analysis is expression-based approach towards the computational functional 
prediction of lincRNA. In this approach, the genes that are co-expressed with the lincRNAs are 
identified to infer the function of the novel lincRNAs. Therefore, the co-expressed lincRNAs are in 
some ways related to that of the co-expressed genes. 
 
The second part of the analysis is implemented based on the sequence information. This is used to 
identify the interaction between different proteins and the Gene/DNA.  In the same way the 
interaction between RNA binding proteins and the lincRNAs are investigated to see how the lncRNA 
influence the gene regulation. Finally the potential miroRNA-lincRNA interaction is taken into 
consideration using a miRanda software which identifies the miRNA targets on lincRNAs based on 
the complementary sequence alignment score and minimum fold energy score. 
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Figure 13. The analysis pipeline towards the functional prediction of novel lincRNAs 
 
Bringing the result from the co-expression analysis, protein-DNA interactions, protein-lincRNA 
interactions and miRNA-lincRNA interactions together, one can predict the possible functional 
insight for the given novel lincRNA transcript. Figure 13 illustrates the analysis pipeline for the 
functional prediction of lincRNAs. 
4.1 Expression based analysis      
The TCGA gene expression count data for glioblastoma is used in [204] which contain the raw 
expression level of genes for each of 169 samples. [Appendix 1] 156 of the samples are from the 
primary solid tumor and the rest of 13 samples are from recursive solid tumor. The other dataset 
 41 
used in this project also contains the raw count expression data for 243 novel transcripts from same 
samples. Out of these transcripts only 53 of them are identified as a long noncoding RNA (lncRNA) 
transcripts [Appendix 1]. The normalized expression data of 534 miRNA transcripts in 137 different 
glioblastoma multiforme samples which are among the samples we study for gene expression and 
transcript expression analysis are another dataset used in this project.  
 
4.1.1 Normalization and pre-processing of raw count expression data 
As the TCGA RNA-seq data for gene expression and the transcript expression are raw count data there 
is a need to perform normalization and preprocessing analysis. Therefore, the DESeq2 R package 
from Bioconductor is used to normalize the dataset.  After normalizing the read count from the 
expression data, the next step is to make the normalized read count to be easier for interpretation. 
In this regards, we can scale the normalized read counts using a logarithmic transformation. The 
following figure shows that the expression values plot after DEseq2 normalization and transforming 
it into a logarithmic scale for the three dataset: gene expression dataset, transcript expression dataset 
and miRNA dataset. 
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Figure 14. DEseq2 normalized and log transformed read counts for gene expression, novel transcript 
expression and miRNA expressions 
 
 
As all the three datasets are of different types, one can expect that the expression levels are not 
absolutely comparable to each other rather there might be a slight difference in their average 
expression levels. The following box plot for each of the three dataset shows that the comparability 
of expression levels across the datasets.   
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Figure 15. Box plots for the gene expression, transcription expression and miRNA expression 
 
4.1.2 Gene differential expression analysis 
 
The differential analysis of the gene among the given samples is calculated by quartile based 
nonparametric model method. The quartile based nonparametric method sorts the expression values 
of the gene among all the samples and compares the group of sample that are on the top 5% of high 
expression and the top 5% of low expression.  Then taking the mean expression among the two 
sample groups for each gene, the differential expression is calculated as the logarithmic fold change 
ratio between the two mean values.  Applying this approach for differential analysis will give a lot of 
flexibility to study what is going on the dataset irrespective of having information about the data 
samples. In this way, different genes might have different sample groups associated with their 
differential value of logarithmic fold changes. 
 
Based on this analysis result, the first 61 genes with high logarithmic fold changes are selected as the 
interesting genes in their respective sample groups. The reason behind selecting the first top 61 
genes is, as there are only 61 transcript that are differently expressed out of 243 novel transcripts 
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and the main research question for this project also lies on this dataset, having same number of 
interesting genes and miRNAs as the number of differently expressed transcript help in the 
subsequent co-expression analysis. Therefore, the following table shows that the first top 61 genes 
with their logarithmic fold changes. 
 
Table 3. Top 61 differentially expressed genes with ensembl id, gene symbol, and fold change 
Gene Symbol       Log fold Change 
"LTF"      11.3642074205527 
"COL6A3"     11.0190144223067 
"POSTN"     10.4981829710414 
"PDGFRA"      9.84543985263434 
"F13A1"      9.7374404284162 
"IGF2"      9.55334306300648 
"COL1A1"     9.50027627479324 
"COL3A1"      9.32970966215948 
"RN7SK"      9.1158443808604 
"CHI3L1"      8.98782027021159 
"CXCL14"      8.91824581507234 
"BCAS1"      8.90807793060724 
"MBP"      8.87567709804349 
"NPTX2"      8.82043483049901 
"SMOC1"     8.77740068108231 
"FMOD"      8.74501375002601 
"LUM"      8.71006150778892 
"SNAP25"      8.65970863179063 
"COL1A2"      8.57867730526177 
"COL5A1"      8.5659300445678 
"LRRN2"     8.51709906203847 
"COL6A2"      8.47002556846174 
"MEG3"      8.41778172021755 
"NCAN"      8.41754899188062 
"ADGRB1"      8.41368640326492 
"THBS1"      8.41004327779113 
"COL7A1"      7.83011425800144 
"ISLR"      7.77533836641366 
"PTPRN"     7.76980198170599 
Gene Symbol       Log fold Change 
"KCNQ2"    8.33818388296843 
"ATP1A3"      8.30191789685553 
"FGFR3"      8.29225466676582 
"MXRA5"     8.26158154552933 
"OLIG2"      8.23721063576021 
"SEZ6"      8.19144975203853 
"OLIG1"      8.18036915760204 
"AVIL"      8.16003353885608 
"RARRES2"     8.15928840573475 
"MOXD1"     8.14771737273237 
"PCSK5"      8.11828585281088 
"B4GALNT1"       8.11544039041408 
"NNMT"      8.0896075541968 
"EGFR"      8.07807112804236 
"COL12A1"      8.07769146698688 
"HSPB8"      8.06737660966411 
"COL14A1"      8.04081221144058 
"HLA-DRB5"       7.99699423664328 
"SEZ6L"      7.97690149381729 
"SPOCD1"      7.93288568306023 
"CHI3L2"      7.93024694934674 
"IGFBP3"      7.91537975165864 
"BCAN"      7.91222139951645 
"PTX3"      7.89781989141177 
"GABBR2"      7.88484517360006 
"EPHB1"     7.8811984482472 
"MFAP2"                         7.85222460081362 
"ANGPTL4"      7.84611117485458 
"FBXL16"      7.8329238759881 
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4.1.3 Transcript differential expression analysis 
 
The same method used in the differential analysis of genes is applied to the differential expression 
analysis of novel transcript samples. Top 61 novel transcripts with the highest fold change are 
considered to be list of interesting novel transcript in their corresponding sample groups. The 
following table illustrates the lists of interesting novel transcript. 
 
Table 4. List of top 61 novel transcripts with their logarithmic fold change 
Novel transcript Id  log Fold Change Value 
"TCGA_gbm-21-32283251"  15.0088341771392 
"TCGA_gbm-17-51805501"  14.9834167340625 
"TCGA_gbm-11-24180751"  14.8088531773541 
"TCGA_gbm-17-8682251"   14.6205643198004 
"TCGA_gbm-9-23156751"   12.5927959421181 
"TCGA_gbm-2-123619751"  12.5511991627051 
"TCGA_gbm-3-163945501"  12.5339632555393 
"TCGA_gbm-12-69383001"  12.5212581678299 
"TCGA_gbm-X-151738001"  12.4738008608724 
"TCGA_gbm-Y-7085501"        12.4438824448183 
"TCGA_gbm-X-144413251"  12.367483007346 
"TCGA_gbm-12-38495001"  12.3657414672672 
"TCGA_gbm-16-64693251"  12.2999949885017 
"TCGA_gbm-7-154817501"  12.2790623894994 
"TCGA_gbm-2-153081251"  12.2768513869177 
"TCGA_gbm-4-130546751"  12.2618011071953 
"TCGA_gbm-10-109839251" 12.2594122648908 
"TCGA_gbm-7-54753751"   12.2241524496637 
"TCGA_gbm-8-37946001"   11.6130987942092 
"TCGA_gbm-3-28093501"   11.5324776871188 
"TCGA_gbm-4-109412001"  11.475670109043 
"TCGA_gbm-15-79922001"  11.2615807643097 
"TCGA_gbm-5-18266001"   11.2330204264745 
"TCGA_gbm-1-5525501"      10.9469062744564 
"TCGA_gbm-8-114503501"  10.9155993254444 
"TCGA_gbm-2-104066001"  10.8868397058844 
"TCGA_gbm-X-110058501"  10.7682877252458 
"TCGA_gbm-2-196150751"  10.5642685979355 
"TCGA_gbm-2-104096501"  10.5191447879974 
"TCGA_gbm-X-141374501"  10.462630074789 
Novel transcript Id  log Fold Change Value 
"TCGA_gbm-X-3135001"      10.1719586190771 
"TCGA_gbm-X-87976751"    10.0014081943928 
"TCGA_gbm-1-5787751"      9.37565333409204 
"TCGA_gbm-3-153501"         8.87892673308683 
"TCGA_gbm-1-68830501"    8.75627831981759 
"TCGA_gbm-13-104880751"  8.20013231456476 
"TCGA_gbm-18-64289001"   7.86781411603516 
"TCGA_gbm-5-63687001"    7.28355142317431 
"TCGA_gbm-21-27587751"   7.01648058864122 
"TCGA_gbm-17-10671251"   6.24253899444822 
"TCGA_gbm-9-42103251"    6.15987133677839 
"TCGA_gbm-21-46975501"   5.96213496979665 
"TCGA_gbm-21-48002751"   5.77942968642626 
"TCGA_gbm-19-46930501"   5.44720132985189 
"TCGA_gbm-1-153561751"   5.43596189543763 
"TCGA_gbm-19-46927751"   5.38760426915573 
"TCGA_gbm-17-30454751"   5.38052274879821 
"TCGA_gbm-22-29576001"   5.2871767517316 
"TCGA_gbm-9-42202751"    5.08834657484054 
"TCGA_gbm-13-110076001"  4.91096771489633 
"TCGA_gbm-2-112797251"   4.86052992695827 
"TCGA_gbm-9-70597501"    4.85435840680639 
"TCGA_gbm-X-53205501"    4.65105169117893 
"TCGA_gbm-9-70631251"    4.63461597035594 
"TCGA_gbm-17-21730501"   4.57041795292621 
"TCGA_gbm-9-42236501"    4.56074492041121 
"TCGA_gbm-9-68284501"    4.51945638970952 
"TCGA_gbm-13-50529001"   4.41069595209362 
"TCGA_gbm-6-28389001"    3.82044308746537 
"TCGA_gbm-8-90598251"    3.06579303170701 
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 "TCGA_gbm-1-120693251"     0 
 
   
4.1.4 miRNA differential expression Analysis 
 
In the same method as that of differential expression analysis with genes and transcript, the first top 
61 highly expressed miRNAs with the highest logarithmic fold changes are illustrated with the 
following table. 
 
Table 5. List of top 61 differently expressed miRNAs with their logarithmic fold change 
miRNA transcripts Log fold Change 
hsa-miR-370      5.747241 
hsa-miR-219      5.709165 
hsa-miR-9        5.249204 
hsa-miR-222      5.143633 
hsa-miR-9*       5.024168 
hsa-miR-338      4.664476 
hsa-miR-21       4.513117 
hsa-miR-451      4.460724 
hsa-miR-26a      4.320483 
hsa-miR-638      4.219905 
hsa-miR-801      4.181721 
hsa-miR-34a      4.168021 
hsa-miR-210      4.111611 
hsa-miR-494      4.041169 
hsa-miR-575      3.892887 
hsa-miR-223      3.755507 
hsa-miR-663      3.728135 
hsa-miR-30a-5p   3.694828 
hsa-miR-155      3.557142 
hsa-miR-149      3.539161 
hsa-miR-17-3p    3.510356 
hsa-miR-126      3.424362 
hsa-miR-195      3.377252 
hsa-miR-20a      3.374421 
hsa-miR-19a      3.352281 
miRNA transcripts Log fold Change 
hsa-miR-181a     3.154147 
hsa-miR-143      3.132416 
hsa-let-7e       3.123281 
hsa-let-7i       3.098401 
hsa-miR-130b     3.095383 
hsa-miR-22       3.079704 
hsa-miR-145      3.069379 
hsa-miR-100      3.056662 
hsa-miR-320      2.989183 
hsa-miR-29b      2.976133 
hsa-miR-487b     2.962234 
hsa-miR-15b      2.952667 
hsa-miR-106a     2.936700 
hsa-miR-99a      2.926939 
hsa-miR-26b      2.925090 
hsa-miR-181c     2.918160 
hsa-miR-23b      2.893517 
hsa-miR-181d     2.828504 
hsa-miR-374      2.822835 
hsa-let-7g       2.813461 
hsa-miR-20b      2.805066 
hsa-miR-768-5p   2.784178 
hsa-miR-19b      2.782292 
hsa-miR-92b      2.775912 
hsa-miR-130a     2.768690 
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hsa-miR-301      3.334236 
hsa-miR-574      3.288644 
hsa-let-7f       3.249088 
hsa-miR-142-3p   3.235623 
hsa-miR-424      3.229504 
 
hsa-let-7a       2.739558 
hsa-miR-181b     2.724688 
hsa-let-7d       2.723302 
hsa-miR-99b      2.690628 
hsa-miR-17-5p    2.689587 
hsa-miR-768-3p   2.675927 
 
 
 
4.1.5 Gene list enrichment analysis 
 
At this point the gene lists of interesting genes are identified according to their log fold change values. 
In this case, only the first top 61 genes with higher log fold change values are identified to be 
interesting genes. From the real biological perspectives, certain set of genes are involved in certain 
biological processes, biological functions or cellular compartments. This gene lists that are involved 
in certain biological ontologies are identified and organized in certain databases. 
 
There are different databases that contain the gene sets for different biological pathways, ontologies, 
genes found in same chromosome or genes sharing same motifs with proteins or miRNAs. For 
example, Molecular Signatures Database (MSigDB) [203], which contains a collection of annotated 
gene lists for gene ontology, pathways, genes found in same chromosome and many more that can be 
used to compare against the gene list of interest. 
 
The Fisher’s exact test p-value with threshold value of 0.05 is applied to find the significantly 
enriched KEGG pathways, gene ontologies, miRNA and transcription factor proteins for the top 61 
differently expressed gene lists.  Table 2 show the enrichment analysis result for the first top 61 
differently expressed gene lists. 
 
Table 7. Significant enrichment results with threshold enrichment p-value of 0.05 
GO MF enrichment result GO BP Enrichment result GO CC enrichment result 
TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE
_ACTIVITY 
METABOTROPIC_GLUTAMATEGABA_B_LIKE_REC
EPTOR_ACTIVITY 
 
INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_BIN
DING 
 
PROTEIN_TYROSINE_KINASE_ACTIVITY 
RNA_METABOLIC_PROCESS 
REGULATION_OF_CELLULAR_PH 
SYSTEM_DEVELOPMENT 
ENZYME_LINKED_RECEPTOR_PROTEIN_SIG
NALING_PATHWAY 
NERVOUS_SYSTEM_DEVELOPMENT 
REGULATION_OF_PROTEIN_AMINO_ACID_PH
OSPHORYLATION 
 
PROTEINACEOUS_EXTRACELL
ULAR_MATRIX 
EXTRACELLULAR_MATRIX_PA
RT 
 
EXTRACELLULAR_REGION           
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RECEPTOR_ACTIVITY 
 
TRANSMEMBRANE_RECEPTOR_ACTIVITY 
 
TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSI
NE_KINASE_ACTIVITY 
SKELETAL_DEVELOPMENT 
REGULATION_OF_PROTEIN_MODIFICATION_
PROCESS 
REGULATION_OF_PHOSPHORYLATION 
 
MULTICELLULAR_ORGANISMAL_DEVELOPM
ENT 
 
CELL_CELL_SIGNALING 
 
PEPTIDE_METABOLIC_PROCESS 
SYNAPTIC_TRANSMISSION 
 
EPIDERMIS_DEVELOPMENT 
 
ANATOMICAL_STRUCTURE_DEVELOPMENT 
 
POSITIVE_REGULATION_OF_EPITHELIAL_CE
LL_PROLIFERATION 
POSITIVE_REGULATION_OF_CELL_MIGRATIO
N 
POSITIVE_REGULATION_OF_ANGIOGENESIS 
 
NEGATIVE_REGULATION_OF_CATALYTIC_AC
TIVITY 
TRANSMEMBRANE_RECEPTOR_PROTEI 
N_TYROSINE_KINASE_SIGNALING_PATHWAY 
 
ORGAN_DEVELOPMENT 
EXTRACELLULAR_REGION_PA
RT 
 
EXTRACELLULAR_MATRIX           
 COLLAGEN 
 
 
KEGG enrichment result miRNA enrichment result TF enrichment result 
KEGG_P53_SIGNALING_PATHWAY  
 
KEGG_FOCAL_ADHESION 
 
KEGG_ECM_RECEPTOR_INTERACTION 
 
KEGG_TYPE_I_DIABETES_MELLITUS 
 
KEGG_GLIOMA 
 
KEGG_MELANOMA 
 
KEGG_BLADDER_CANCER 
 
CTACCTC,LET-7A,LET-7B,LET-7C,LET-
7D,LET-7E,LET-7F,MIR-98,LET-7G,LET-7I 
 
CACTGTG,MIR-128A,MIR-128B 
 
ACTACCT,MIR-196A,MIR-196B 
 
GTGTGAG,MIR-342 
 
GTGACTT,MIR-224 
 
GAGCCAG,MIR-149 
 
 
V$MEF2_01 
V$IK1_01 
  
V$SRF_Q6 
 
V$NKX25_02 
       
V$NRSF_01 
        
V$HNF4_DR1_Q3 
 
V$AP1_Q2_01 
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V$MEF2_Q6_01 
 
GGGYGTGNY_UNKNOWN 
YATTNATC_UNKNOWN  
YCATTAA_UNKNOWN   
SCGGAAGY_V$ELK1_02 
RCGCANGCGY_V$NRF1_Q6  
GGGTGGRR_V$PAX4_03TAAW
WATAG_V$RSRFC4_Q2 
 
4.1.6 Co-expression analysis 
 
The co-expression analysis of two expression values of different data type, such as, gene expression 
and lincRNA expression values, gene expression and miRNA expression values or lincRNA and 
miRNA expression values, can be analyzed using either Pearson’s correlation or one can apply a 
mutual information based approach to find the similarity between the two datasets. 
5.1.6.1 Correlation based co-expression analysis 
 
Implementing Pearson’s correlation based measure of association in R on the normalized gene 
expression data and on the novel transcript data, any associations with greater that 0.5 Pearson’s 
correlation coefficient (r) and less than -0.5 Pearson’s correlation coefficient is assumed to be 
significant for the further analysis steps. Figure 16 shows distributions of the correlation coefficient 
values for the gene-novel transcripts, gene-miRNA and miRNA-novel transcripts together with the 
co-expressing pairs of transcripts.  
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Figure 16. Correlation based a co-expression analysis 
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From the result shown in the figure 16, out of all genes, there are only three genes that are co-
expressed or highly correlated with the threshold correlation coefficient of 0.5, either in a positive or 
negative way, with the novel transcripts. These genes are AVIL, THBS1 and IGFBP3. Only THBS1 gene 
is co-expressed with the novel lincRNA TCGA_gbm-3-153501 that is identified by Novellette 
algorithm.  
 
 
4.1.6.2 Mutual information based co-expression analysis 
 
Applying ARACNE algorithm in R to identify the co-expression of the genes with novel transcripts 
and miRNAs of interest, the result of the analysis is summarized in the figure 17 below. As the dataset 
in which the co-expression analysis is made are of different types, it is obvious that the mutual 
information threshold is small. For the gene-novel transcript co-expression analysis the mutual 
information threshold is 0.2. The threshold values of mutual information used for the gene-miRNA 
and miRNA-novel transcript are 0.4 and 0.26 respectively.  
 
 
Figure 17. Mutual information based co-expression with ARSENE 
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Looking at the co-expression between the genes and novel transcripts with the cutoff threshold 
mutual information of 0.2, only five genes namely, PCSK5, RARRES2, IGFBP3, GABBR2 and HSPB8 are 
co-expressed with one of the novel transcript at hand as it is shown in the figure 17.  
 
 
 
4.2 Sequence based analysis 
4.2.1 Protein-DNA interaction 
 
Moving from expression-based analysis to sequence based analysis, the interaction between the DNA 
sequence of the promoter regions of interesting genes and different type of proteins can be examined. 
In this regards, the DNA of the promoter regions of the interesting genes might interact with different 
transcription factor proteins, RNA binding proteins or other types of protein that might affect the 
function of the lincRNA directly or indirectly. Therefore, the investigation of the involvement of 
different proteins interaction with lincRNA will be the crucial part in revealing the possible functional 
mechanism of the lincRNA. 
 
In PWM model, the position frequency matrices are constructed by aligning the sets of binding sites 
from different experiments given the background distribution. There are several databases with PFM 
or PWM for different proteins that interact with DNA based on the chip-seq experiments or literature 
mining. Some of the PWM databases are: 
 
❏ UNIPROBE is one of the database with both experimental and literature mined PWMs 
❏ JASPAR is the other one with 123 PFM matrices for different organism based on the SELEX 
method 
❏ TRANSFAC is not open source database which has about 848 matrices for different organism.  
❏ hPDI(Human Protein-DNA Interactome) with 17,718 preferable DNA binding sequences 
for 1013 human DNA-binding proteins 
 
As hPDI database has abundant and experimentally validated PFM for human DNA-binding proteins, 
this database is used to scan specific protein binding motif. In this project, 437 experimentally 
verified human protein-DNA binding motifs are extracted from hDPI database. [189]. The 437 
proteins are of different types: 
 
■ 52 mitochondrial protein 
■ 80 RNA binding protein 
■ 18 chromatin associated protein 
■ 5 kinase protein 
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■ 14 Nucleic Acid binding proteins 
■ 55 other non-transcription factor proteins 
■ 212 Transcription factor proteins 
 
A gene is a nucleotide sequence of specific region in the DNA. For protein coding genes, the structure 
of a gene is composed of four specific parts as shown in the figure below. 
 
Figure 18. Protein coding gene structure 
 
The promoter region at the 5’ part of the gene structure is a place where the transcription factor 
proteins bind and send a signal for the RNA polymerase to start transcription right from the start 
codon. The start codon is a three nucleotide base sequence, in most case “AUG”, in which the 
transcription begins. Stop codon at the 3’ part of the gene in the other hand is also the three-
nucleotide base sequences, in most case “TAG“, where the RNA polymerase stops the transcription. 
The genomic region between the start and stop codon in which transcription takes place is known as 
coding region or open reading frame (ORF).    
 
Scanning the promoter regions of the interesting genes from the previous analysis pipeline might 
reveal the proteins that play major role in the transcription of those specific genes. In addition, 
scanning the novel lincRNA sequences with proteins might unveil the function of the lincRNA in 
transcriptional interference. 
 
In order to extract the genomic sequences of the highly differentially expressed genes, the BioMart 
package from bioconductor is used.  The sequence of 2000 nucleotides upstream from the 
transcription start site or start codon are extracted as the promoter sequence. In the same way, for 
the retrieval of the lincRNA sequences, the BEDtools from samtools together with the bed file with 
exonic coordinate of the lincRNA’s as identified in [204] is used to query it from the HG19 genome 
assembly, the same genome assembly that is used in [204]. 
 
Applying the PWM model in calculating the PWM score for each promoter region of the first top 61 
highly expressed genes in both strand and calculating the significant PWM score will identify the 
proteins that are interacting with the promoter region of the genes. Thus, this protein-DNA 
interaction, when it is integrated with the result from lincRNA-protein interaction, might provide 
insight in the possible transcriptional interference functional mechanism of the lincRNA. 
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The PWM for 437 human protein-DNA interaction motifs are implemented in R using the PFMs from 
the hPDI database. Chunking the promoter sequences with the length of the binding motif to form a 
scanning window for the PWM, in all possible chunks or window the PWM score is calculated both in 
the forward and reverse strand of the promoter sequence.  
 
Once the PWM score is calculated for each of the proteins binding motifs and the promoter regions 
of the genes of interest, the next step is to figure out which of the protein binding motifs or windows 
has significant PWM score. In this regards, the significant protein binding motifs can be identified by 
randomly scanning equal length of sequence as promoter sequence from any intergenic region of 
DNA with the protein binding motif and compare how the PWM scores of the randomly scanned and 
that of the promoter regions of the gene differ by calculating the p-value of significance. 
 
The control nucleotide sequence is taken from the chromosome 4 starting from 54985200 to 
54987200 nucleotide coordinate. The p-value of significance for the PWM score is calculated using 
the nonparametric Wilcoxon statistical testing method. The following table summarizes the 
significant proteins with binding site in both strands of promoter regions of the 5 highly differentially 
expressed genes. Parts of the table are omitted due to large number of rows. 
 
Table 8. Proteins with the binding site in the top four highly differentially expressed genes 
LTF gene COL6A3 gene POSTN gene PDGFRA gene 
protein       p_value 
AFF4        1.698688e-05 
AKR1A1   1.357184e-04 
BAT4        1.374678e-05 
C9orf156  2.156080e-08 
CCDC25    6.816969e-03 
CYCS   8.203411e-04 
 
 
Protein    p_value 
AGGF1    7.306652e-08 
AKR1A1  1.607913e-03 
ASCC1    8.955983e-08 
CAT 5.340410e-06 
CYCS      6.184013e-03 
DIS3        7.269489e-09 
Protein       p_value 
BAT4    6.732246e-10 
BOLL    2.568877e-05 
C9orf156   2.279876e-07 
CDK2AP1  4.713121e-08 
DIABLO     7.039418e-05 
FAM127B   7.422401e-03 
Protein     p_value 
TAF9        0.006032266 
4.2.2 Protein-lincRNA interaction 
 
The biological binding principles behind the proteins and the RNA molecules are explained in terms 
of the electrostatic interactions, hydrogen bonding, secondary & tertiary structures and the van der 
waal's interactions. The computational prediction of the RNA-protein interactions are to some extent 
takes the above principles into considerations. The computational approach to predict the RNA-
protein interactions are carried out in two ways, either it predicts the RNA binding protein (RBP) 
motifs on the RNA molecules or it predicts the possible RNA binding motifs on the protein molecules. 
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In this project, the computational prediction of RNA-protein interaction in search of the RNA binding 
protein motifs on the novel lincRNAs is carried out based on only sequence information of the 
lincRNA molecules. If the structural aspect of the RNA-protein interaction is ignored, the methods to 
implement the RBP binding motifs on the RNAs are similar to that of the DNA-protein interaction. 
 
As the DNA binding proteins there are different databases that hold a CLIP-seq experimental or 
literature mined RNA-protein interaction data that contains the PFM of different proteins that bind 
to the RNA molecules. Some of the database that provides the PFM of the interaction includes: 
 
 
✓ RNAcontext 
✓ MEMERIS 
✓ MatrixREDUCE 
✓ RNAcompete 
✓ RBPDB 
 
One thing that differentiate the PWM model applied in the protein binding motif scanning on DNA 
from RNA binding proteins scanning on RNA is that in the case of scanning for RNA binding proteins 
on RNA there is no reverse strand scanning as the RNA molecule is a single stranded molecule. In 
addition to that, the PFM contains uracil (U) base pair instead of thymine (T) base pair. 
 
The PFM for 53 experimentally verified RBPs from the RBPDB database and 102 PFMs for RBPs from 
RNAcompete database is used in the RBP site scanning on the 17 novel lincRNA sequences. The 
lincRNA sequences are extracted from the HG19 genome assembly based on the genomic coordinate 
identified by [204]. Out of the top 61 differentially expressed novel transcripts, only 27 of them are 
found to be the novel lincRNA transcript. 
 
"TCGA_gbm--2--104066001"   "TCGA_gbm--2--104096501"   "TCGA_gbm--3--153501" 
"TCGA_gbm--1--68830501"   "TCGA_gbm--13--104880751”  "TCGA_gbm‐-18--64289001" 
"TCGA_gbm--5--63687001"   "TCGA_gbm--21--27587751"   "TCGA_gbm--17--10671251" 
"TCGA_gbm--21--46975501"   "TCGA_gbm--21--48002751"   "TCGA_gbm--1--153561751" 
"TCGA_gbm--19--46927751"   "TCGA_gbm--17--30454751"   "TCGA_gbm--22--29576001" 
"TCGA_gbm--9--42202751"   "TCGA_gbm--13-‐110076001”  "TCGA_gbm--2--112797251" 
"TCGA_gbm--9--70597501"   "TCGA_gbm--X--53205501"   "TCGA_gbm--9--70631251" 
"TCGA_gbm--17--21730501"   "TCGA_gbm--9--42236501"   "TCGA_gbm--9--68284501" 
"TCGA_gbm--13--50529001"   "TCGA_gbm--8--90598251"   "TCGA_gbm--1--120693251" 
 
Out of the above 27 identified novel lincRNAs only 17 of them are with enough information on the 
transcription direction, start and end coordinate of their exons. These 17 novel transcripts with 
enough detail information are: 
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"TCGA_gbm--2--104096501"   "TCGA_gbm--3--153501"  "TCGA_gbm--5--63687001" 
"TCGA_gbm-21--27587751"   "TCGA_gbm--17--10671251"  "TCGA_gbm--1--153561751" 
"TCGA_gbm--17--30454751"   "TCGA_gbm--8--90598251"  "TCGA_gbm--22--29576001" 
"TCGA_gbm--2--112797251"   "TCGA_gbm--9--70597501"  "TCGA_gbm--9--70631251" 
"TCGA_gbm--17--21730501"   "TCGA_gbm--9-42236501"  "TCGA_gbm--1--120693251" 
"TCGA_gbm--9--68284501"   "TCGA_gbm--13--50529001" 
 
The genomic locations of the above novel lincRNAs are given in the following bed file format table.   
 
Table 9. Genomic location of the novel lincRNAs 
novel lincRNA name    Chr     Start        End      Exons       Strand 
 
TCGA_gbm-1-120693251   chr1    120693368    120697115    TCGA_gbm-1-120693251Ex1      + 
TCGA_gbm-1-153561751 chr1    153557550    153562200    TCGA_gbm-1-153561751Ex1      - 
TCGA_gbm-2-104096501 chr2    104066248    104066478    TCGA_gbm-2-104096501Ex1      - 
    chr2    104066930    104067073    TCGA_gbm-2-104096501Ex2      - 
    chr2    104096754    104097000    TCGA_gbm-2-104096501Ex3      - 
TCGA_gbm-2-112797251 chr2    112796951    112798143    TCGA_gbm-2-112797251Ex1      + 
TCGA_gbm-3-153501 chr3    153750    154250          TCGA_gbm-3-153501Ex1        - 
TCGA_gbm-5-63687001 chr5    63682339      63688666      TCGA_gbm-5-63687001Ex1       + 
TCGA_gbm-8-90598251 chr8    90598127      90600261      TCGA_gbm-8-90598251Ex1       - 
TCGA_gbm-9-70597501 chr9    70596970      70600171      TCGA_gbm-9-70597501Ex1       - 
TCGA_gbm-9-70631251 chr9    70631128      70631944      TCGA_gbm-9-70631251Ex1       + 
TCGA_gbm-9-42236501 chr9    42235789      42237190      TCGA_gbm-9-42236501Ex1       - 
TCGA_gbm-9-68284501 chr9    68284810      68285084      TCGA_gbm-9-68284501Ex1       + 
TCGA_gbm-13-50529001 chr13    50528852    50530202      TCGA_gbm-13-50529001Ex1      - 
TCGA_gbm-17-30454751 chr17    30454391    30455334      TCGA_gbm-17-30454751Ex1      - 
TCGA_gbm-17-10671251 chr17    10670126    10672237      TCGA_gbm-17-10671251Ex1      - 
TCGA_gbm-17-21730501 chr17    21730767    21731530      TCGA_gbm-17-21730501Ex1      + 
TCGA_gbm-21-27587751 chr21    27588024    27589704      TCGA_gbm-21-27587751Ex1      + 
TCGA_gbm-22-29576001 chr22    29574536    29576616      TCGA_gbm-22-29576001Ex1      + 
 
 
Once the sequence of each transcript is retrieved from the corresponding hg19 assembly using 
samtools, it will be converted into the RNA sequence. The Biostrings R package from the 
bioconductor is used to convert the DNA sequences into the RNA sequences.     
 
In the same ways as the PWM score is calculated for the protein-DNA interactions, the PWM score is 
calculated for RBPs and the novel lincRNAs. Once having the PWM scores for each of the window in 
the lincRNA sequence, the need to calculate the significant motif hit is the next step. As it is done for 
the DNA-protein interactions, in this case the reference or control sequence is taken from any random 
exonic sequence from the genome with equal sequence length with the lincRNA. After the Control 
sequence is extracted from the genomic exonic region, it is then converted to RNA sequence using 
the Bioconductor’s Biostrings package in R.    
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Then, having sequence length of the control sequence the same as that of each lincRNAs, the RBP 
motif scan is carried out by calculating the PWM score for each windows or motifs on the control 
sequence. Then the PWM score of both the lincRNA sequence and that of the control sequence are 
used to find out which RBPs have statistically significant binding site. Based on this approaches, the 
lincRNAs with the statistically significant binding hit for certain RBPs from the PWM model are fully 
illustrated in the appendix 1. 
 
In order to show the RBPs that have significant binding site on the lincRNAs, only the significant RBPs 
that have significant binding site on the top 5 highly differentially expressed novel lincRNAs with the 
fold changes illustrated in the table below are selected due to large table columns.       
 
 
Table 10. top 5 DE novel lincRNA 
top 5 DE novel lincRNA  Log fold Change 
TCGA_gbm-2-104096501   
TCGA_gbm-3-153501    
TCGA_gbm-5-63687001 
TCGA_gbm-17-10671251 
TCGA_gbm-21-27587751     
10.519145 
8.878927 
7.283551 
6.242539 
7.016481 
 
 
 
 
Table 11. Proteins with binding site on novel lincRNAs based on PFM from RBPDB database 
TCGA_gbm-2-104096501 TCGA_gbm-3-153501 TCGA_gbm-17-10671251 TCGA_gbm-5-63687001 
RBP                p-value 
A2BP1          1.483784e-04 
KHDRBS3    4.143959e-12 
QKI                5.165369e-03 
ZFP36           2.752346e-04 
SFRS2           1.213953e-08 
SFRS1           3.413817e-08 
EIF4B           4.044587e-05 
IGF2BP1      6.615535e-03 
KHDRBS3    4.083160e-11 
NONO          2.014912e-22 
HNRNPA     1.658171e-11 
YBX1            1.550585e-20 
KHDRBS3   1.672579e-13 
RBP               p-value 
A2BP1          7.994252e-04 
KHDRBS3    4.128248e-07 
QKI                8.723493e-04 
SFRS2           6.411125e-05 
SFRS1           1.541553e-03 
EIF4B            1.251044e-03 
IGF2BP1       2.399029e-03 
KHDRBS3    1.651886e-06 
NONO           3.719077e-11 
HNRNPA1   4.037018e-06 
YBX1            9.888623e-16 
KHDRBS3   3.539882e-08 
SNRPA         4.911790e-03 
RBP              p-value 
A2BP1         2.041465e-09 
KHDRBS3   2.437164e-13 
QKI               1.350722e-05 
SFRS2          9.231877e-09 
SFRS1          7.744355e-07 
EIF4B          8.207584e-04 
IGF2BP1     2.053731e-03 
KHDRBS3   1.260073e-10 
NONO          2.080393e-16 
HNRNPA1   5.729528e-10 
YBX1            2.500646e-25 
KHDRBS3   1.584971e-05 
SNRPA        9.113207e-03 
RBP                p-value 
PABPC1       6.497751e-21 
A2BP1         6.583837e-03 
KHDRBS3   2.670768e-17 
ZFP36         5.998443e-17 
SFRS1         4.458376e-80 
EIF4B         2.182950e-27 
IGF2BP1    1.939343e-05 
KHDRBS3  1.202122e-06 
QKI              2.148875e-08 
NONO         3.498104e-43 
HNRNPA1  2.131723e-33 
YBX1            2.545392e-58 
SNRPA         2.002908e-04 
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RBM4           5.497882e-06 
SNRPA         9.562542e-03 
MBNL1        3.933100e-17 
NOVA2         7.255056e-05 
ELAVL2       3.393680e-05 
SFRS2          2.334640e-03 
SFRS7          1.252532e-06 
RBMX          8.883769e-09 
YTHDC1     7.060927e-30 
RBMY1A1  4.978744e-08 
ZRANB2     8.907087e-04 
 
MBNL1        2.548278e-06 
NOVA2        1.450842e-04 
ELAVL2       3.028037e-03 
RBMX          8.545470e-08 
YTHDC1     2.082768e-14 
RBMY1A1  1.024184e-04 
MBNL1       1.254569e-07 
NOVA2        2.555746e-06 
ELAVL2      6.309175e-04 
SFRS2          2.575048e-04 
SFRS7         1.620752e-05 
RBMX         2.361421e-12 
YTHDC1    7.869544e-16 
NCL            6.003961e-03 
RBMY1A1 2.492161e-08 
KHDRBS3   5.545314e-16 
SFRS1          1.592015e-06 
RBM4          4.632046e-75 
PTBP1        7.694061e-03 
ELAVL1      9.026422e-04 
SFRS13A    2.145211e-22 
PABPC1     3.329851e-05 
SFRS1        2.902830e-15 
SFRS7       1.079706e-03 
SFRS2       1.135660e-10 
ZFP36       1.946519e-20 
SNRPA       5.603732e-07 
FUS            2.038293e-13 
MBNL1     1.405556e-91 
ELAVL2    1.310357e-06 
SFRS2       2.967565e-20 
SFRS7       3.758398e-43 
SFRS9       6.014165e-07 
RBMX        8.173692e-14 
YTHDC1   3.241395e-151 
NCL            2.742761e-04 
RBMY1A1  6.750634e-14 
RBMY1A1  1.562333e-13 
ZRANB2     7.263636e-55 
 
    
 
4.2.3 miRNA-lincRNA interaction 
 
RNA-RNA interactions are one of the mechanism by which ncRNAs achieve their diverse functions. 
One of the well-studied functions of miRNA on protein coding genes is destabilizing and repressing 
the translation of protein coding transcripts by binding at the 3’ UTR regions of the mRNAs. However, 
recent studies are showing that miRNAs has influence on the function of the lncRNAs and lncRNA 
also in some way influence the function of the miRNA. The stability of the lncRNAs in some case will 
be degraded by the interaction with miRNAs. In the other hand, lncRNAs might act as the miRNA 
decoy and some of them are degraded to produce miRNAs. [190] 
 
In this project, the interaction of novel lincRNAs with the miRNAs are investigated to examine their 
functional effect on gene expression and in turn reveal the molecular and functional mechanisms of 
the novel transcripts of interest. The computational approach to predict the interaction of lncRNAs 
and miRNAs is based on the identification of miRNA binding target site on the lncRNAs.  miRanda is 
an algorithm developed by Memorial Sloan-Kettering Cancer Center, New York  and distributed 
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under GNU Public License to scan the miRNA target on other RNA sequences. It utilizes the dynamic 
programming alignment together with the thermodynamics approach to find the possible miRNA 
binding site on the reference RNAs. 
 
In miRanda, the potential miRNA target site is identified in two step strategies. In the first step the 
algorithm carries out the dynamic programming local alignment between miRNA sequences and the 
reference.  In the first step the algorithm produces the alignment score based on the sequence 
complementarity, gap desired and gap penalty. The RNA sequence complementaries used in the  
alignment are A:U, G:C and G:U. 
 
 
 
Once the target scanning passed the minimum threshold of alignment score from step one, the 
algorithm will proceed to the second step in which the thermodynamic stability of RNA duplexes 
based on these alignments are examined. The folding routine from RNAlib library that is the 
ViennaRNA package written by Ivo Hofacker is utilized to generate constrained fictional single-
stranded RNA composed of the query sequence, a linker and the reference sequence. This structure 
is then folded using RNAlib and the minimum free energy (DG kcal/mol) is calculated. The final result 
is composed of the target sites with less than the minimum fold energy threshold value. The 
command used to scan for the miRNA target site on the lincRNA of interest using the miRanda 
software is given below: 
 
miranda miRNASeqmiRbaseDB.fasta LincRNASeqHg19.fasta -sc 220 -en -110 -go -9 -ge -4 -out myresult.txt 
 
where: 
miRNASeqmiRbaseDB.fasta is the multiple miRNA sequences  that are differently   expressed 
in the glioma TCGA samples and   
LincRNASeqHg19.fasta is the 17 lincRNAs that are identified by the seppala’s work. 
-sc 200 is the minimum alignment score threshold and -en -110 is the minimum fold energy 
threshold 
-out myresult.txt option will write the output to the specified text file. 
-go -9 is the gap open penalty 
-ge -4 is the gap extend penalty 
 
One of the output for the above command that satisfy the threshold value for both the maximum 
alignment score and minimum folding energy is shown below. 
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The miRNAs and the novel lincRNAs that has passed the minimum alignment scores threshold and 
the minimum folding energy across the top 61 differently expressed miRNAs and the 17 novel 
lincRNAs in miRanda algorithm are illustrated in table 12. 
 
 
Table 12. miRNA with binding site on novel lincRNAs by miRanda algorithm 
miRNA seq lincRNA seq Alignmet 
Score 
min Folding 
Energy 
Strand 
 
Len1 Len2 Positions 
hsa-mir-638 TCGA_gbm-13-
50529001 
223.00 -114.34 658 100 1365 1073 
hsa-mir-181d TCGA_gbm-22-
29576001 
223.00 -122.98 578 137 2095 578 
 
hsa-mir-181d TCGA_gbm-21-
27587751 
221.00 -118.22 577 137 1695 748 
hsa-mir-181c TCGA_gbm-13-
50529001 
268.00 -111.15 199 110 1365 93 
hsa-mir-181d TCGA_gbm-17-
10671251 
252.00 -136.84 575 137 2126 852, 1294 
1547,1139 
hsa-mir-210 TCGA_gbm-17-
30454751 
222.00 -118.02 217 110 943 413 
 
hsa-mir-210 TCGA_gbm-17-
21730501 
225.00 -117.15 219 110 778 74 
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Based on the result from miRanda algorithm, hsa-mir-181d, miRNA, is predicted to have an 
interaction with TCGA_gbm-22-29576001, TCGA_gbm-21-27587751 and TCGA_gbm-17-10671251 
novel lincRNAs. hsa-mir-210 also have a binding site on TCGA_gbm-17-21730501 and TCGA_gbm-
17-30454751 lincRNAs. hsa-mir-638 is expected to interact with TCGA_gbm-13-50529001 and hsa-
mir-181c is predicted to interact with TCGA_gbm-13-50529001.  
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5 RESULT           
The functional prediction of the novel lincRNA transcripts that are identified by [204] is carried out 
by integrating the different results in the analysis pipeline such as gene list enrichment analysis, co-
expression analysis, protein-DNA interaction, protein-lncRNA interaction and miRNA-lincRNA 
interaction.   
 
The result from gene list enrichment analysis reveals that relation between the first 61 highly 
differentially expressed genes and the Gene ontologies and pathways associated with it. Based on 
this result the list of highly differently expressed genes have pathways and gene ontologies related 
to the glioblastoma.   
 
As one of the mechanism to predict the functions of the lincRNA is examining the functionality of the 
co-expressed gene along with the lincRNA, the functionality of the gene that is co-expressed with the 
novel transcript are predicted to be the possible function of the newly identified novel lincRNA. The 
result from the protein-DNA and protein-lincRNA interaction assert the transcriptional interference, 
posttranscriptional regulation and the roles of the novel lincRNAs in mRNA splicing.  As the 
interaction of the miRNA with lincRNA has a destabilizing effect on lincRNA and in return it affects 
the normal function of the miRNA, it is possible to predict that functions associated to the interacting 
miRNA might infer functional mechanism of the newly identified lincRNA. In addition, lincRNAs and 
miRNAs might be involved in competition for binding site on mRNA.   
 
As it is illustrated in table 7 of the gene list enrichment analysis result, the first 61 highly differentially 
expressed gene lists are enriched among the gene ontology molecular functions of  transmembrane 
receptor protein kinase activity, transmembrane receptor protein tyrosine kinase activity, 
transmembrane receptor activity and insulin like growth factor receptor  binding. 
 
The gene ontology biological processes in which the top 61 differently expressed genes involved are 
organ development, skeletal development, nervous system development, anatomical structure 
development, enzyme linked receptor protein signaling pathway, RNA metabolic process , regulation 
of cellular PH, regulation of protein modification process, regulation of phosphorylation, cell-cell 
signaling, synaptic transmission, epidermis development, positive regulation of the epithelial cell 
proliferation,  positive regulation of cell migration, positive regulation of angiogenesis, negative 
regulation of catalytic activities and transmembrane receptor protein trypsin kinase signaling 
pathway. 
 
The KEGG enrichment pathway analysis result that are shown in the table 7 indicates that the top 61 
highly differentially expressed genes are involved in KEGG glioma pathway, KEGG ECM receptor 
interaction pathway,  KEGG p53 signaling pathway, KEGG melanoma pathway, KEGG bladder cancer 
pathway, KEGG focal adhesion pathway and KEGG type 1 diabetes mellitus pathway. 
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As the co-expression analysis of the novel lincRNAs with the genes give insight in the possible 
functional mechanism of the newly discovered lincRNA, the correlation based co-expression analysis 
result with the threshold correlation coefficient of 0.5 from figure 19 shows that the THBS1 gene and 
TCGA_gbm--3--153501 novel lincRNA are co-expressed.  
 
 
Figure 19. Co-expression network between the novel lincRNAs and genes with cutoff correlation coefficient of 0.5 
 
Looking at the co-expression networks of genes with the miRNA in figure 20 with a threshold 
correlation coefficient of 0.5, THB1 gene is again co-expressed with the has-miR-145 microRNA. The 
IGF2 gene is co-expressed with the has-miR-301  
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Figure 20. Gene-miRNA network with threshold correlation coefficient of 0.5 
 
Out of these all miRNAs that are co-expressed with genes there are only four of them that are 
among top ten highest log fold change values.  The sub-network of co-expression between the top 
ten highest log fold change miRNAs and genes are shown in the figure below. 
 
 
Figure 21. The sub network of the top 10 highest log fold change valued miRNA with genes 
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As it is show in the figure 21, hsa-miR-222 is co-expressed with POSTN, hsa-miR-219 with MBP and 
hsa-miR-338 is co-expressed with BCAS1 genes. Looking at the transcript and miRNA co-expression 
in figure 22, there are two miRNAs that are co-expressed with the transcripts with threshold 
correlation coefficient of 0.5. 
 
 
Figure 22. The network of co-expression between the novel transcripts and miRNAs with threshold 
correlation coefficient of 0.5 
 
As it is shown in the figure 22 none of the novel lincRNA transcripts identified with Novellett 
algorithm are identified to be co-expressed with any of the miRNAs. The co-expression network 
between the miRNA and transcripts shows that hsa-miR-17-3p is co-expressed with TCGA_gbm-13-
110076001 and hsa-miR-487b is co-expressed with both TCGA_gbm-21-32283251 and TCGA_gbm-
11-24180751. 
 
The mutual information based co-expression analysis with the minimum threshold mutual 
information of 0.2 for gene and novel transcript association is shown in figure 23. Out of the novel 
transcripts that are co-expressed with the genes, there is only one novel lincRNA transcript which is 
TCGA_gbm-21-27587751 co-expressed with RARRES2 gene as it is illustrated in figure 23. 
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Figure 23. Co-expression of top 10 genes and miRNAs with novel transcripts and novel lincRNAs   
 
 
Looking at the miRNA and novel transcript co-expression shown in figure 17 with the threshold 
mutual information of 0.26, there are four miRNAs, hsa-miR-9*, hsa-miR-210, hsa-miR-142-3p and 
hsa-miR-99a that are co-expressed with TCGA_gbm-19-46930501, TCGA_gbm-2-104096501, 
TCGA_gbm-16-64693251 and TCGA_gbm-9-23156751 respectively. As it is shown in the figure 23, 
TCGA_gbm-2-104096501 is the only novel lincRNA that is co-expressed with hsa-miR-210 miRNA. 
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Taking cutoff threshold mutual information to 0.4, the co-expression between the gene and miRNA 
are illustrated in the figure 23. COL6A3 gene is co-expressed with hsa-miR-222, hsa-miR-210 and 
hsa-miR-494. In the same way, BCAS1 is co-expressed with hsa-miR-338 and hsa-miR-219 miRNAs. 
MBP gene is expressed with hsa-miR-219 and hsa-miR-338 miRNAs while F13A1 genes is co-
expressed with hsa-miR-210, hsa-miR-222 and hsa-miR-494 miRNAs. 
 
As it is illustrated in the figure 23, COL6A3 and F13A1 genes are among the top 10 differentially 
expressed genes that are co-expressed with hsa-miR-222, hsa-miR-494 and hsa-miR-210 while hsa-
miR-222, hsa-miR-338 and hsa-miR-219 miRNAs are among top 10 differentially expressed miRNAs 
that are co-expressed with COL6A3, F13A1, MBP and BCAS1. 
 
Based on the result from the DNA-protein and protein-lincRNA interaction, it is possible to predict 
the transcriptional interference of certain proteins that in turn reveals the possible functional 
mechanisms of the lincRNA. Hence, identifying proteins that have binding site on both the promoter 
regions of the highly differentially expressed genes and on the newly identified lincRNAs are in some 
way highlights the possible functional roles of the lincRNAs. Table 7 illustrates proteins that have a 
binding site on both the novel lincRNA and promoter regions of the highly differentially expressed 
genes. 
 
Table 7. Proteins that have binding site on both novel lincRNA and promoter regions of top 10 DE expressed genes 
novel lincRNA Top 10 DE 
Genes 
common binding proteins 
 
TCGA_gbm-1-120693251,TCGA_gbm-8-90598251, TCGA_gbm-
17-21730501 
IGF2 "DAZAP1", "MSI1", "RBM3", 
"RBM8A", "TIA1" 
F13A1, 
COL1A1, 
COL3A1 
“TIA1” 
TCGA_gbm-1-153561751, TCGA_gbm-5-63687001,TCGA_gbm-
22-29576001, 
F13A1, 
COL1A1, 
COL3A1 
“TIA1” 
IGF2 "BRUNOL5", "DAZAP1", "MSI1", 
"RBM3", "RBM8A", "TIA1" 
TCGA_gbm-2-104096501,TCGA_gbm-2-112797251, TCGA_gbm-
9-70597501,TCGA_gbm-9-42236501, TCGA_gbm-9-68284501 
IGF2 "DAZAP1", "MSI1", "RBM3", 
"RBM8A" 
TCGA_gbm-2-112797251, TCGA_gbm-8-90598251 IGF2 "BRUNOL5", "MSI1", "RBM3", 
"RBM8A" 
TCGA_gbm-3-153501, IGF2 "MSI1", "RBM3", "RBM8A 
TCGA_gbm-9-70631251 IGF2 "DAZAP1", "RBM3", "RBM8A" 
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TCGA_gbm-13-50529001 IGF2 "DAZAP1", "RBM8A” 
TCGA_gbm-1-153561751, TCGA_gbm-2-112797251,TCGA_gbm-
9-70631251,TCGA_gbm-9-70597501,TCGA_gbm-21-27587751 
IGF2, COL3A1 ACO1(RBPDB) 
 
 
Insulin-like growth factor receptor (IGF2) gene is one of the genes that are highly differentially 
expressed as it is shown in the previous analysis steps and it has the RBP binding site in its promoter 
region. IGF2 protein hormone is preferentially expressed after birth in the liver and it is involved in 
regulation of cellular proliferation growth, migration, differentiation and survival. Adult IGF2 
expression occurs in liver and in epithelial cells lining the surface of the brain. IGF2 is imprinted and 
is expressed exclusively from the paternal allele except in adult liver and central nervous system, 
where it is expressed biallelically [193]. This gene has MSI1, RBM3, RBM8A, BRUNOL5 and DAZAP1 
proteins that have binding sites in both its promoter region and the identified novel lincRNA. 
 
Factor XIII, a1 subunit (F13A1) is another gene with common protein binding site in its promoter 
region and novel lincRNAs as it is shown in table 7 that encodes the coagulation factor XIII A subunit. 
Coagulation factor XIII is an enzyme activated in the blood coagulation cascade. This enzyme acts as 
a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking 
between fibrin molecules, thus stabilizing the fibrin clot. Defects in this gene can result in a lifelong 
bleeding tendency, defective wound healing, and habitual abortion. [194] 
 
Collagen, type I, alpha 1(COL1A1) is a gene among highly differentially expressed genes which 
encodes to the pro-alpha1 chains of type I collagen protein which is the most abundant protein in the 
human body and it is a substance that holds the whole body together. It is found in most connective 
tissues and it is abundant in bone, cornea, dermis and tendon. Defect on this gene results in a 
particular type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated 
expression of the growth factor. [193] collagen, type III, alpha 1(COL3A1) gene also encodes for the 
pro-alpha1 chains of type III collagen, a fibrillar collagen that is found in extensible connective tissues 
such as skin, lung, uterus, intestine and the vascular system, frequently in association with type I 
collagen. [195] 
 
TCGA_gbm-2-104096501, TCGA_gbm-3-153501, TCGA_gbm-5-63687001 and     TCGA_gbm-17-
10671251, among the first top 5 differentially expressed novel lincRNAs, and IGF2 gene, among the 
first top 10 differentially expressed gene, have common protein binding site for MSI1, RBM3 and  
RBM8A proteins. MSI1 is an RNA binding protein that plays a role in the proliferation and 
maintenance of stem cells in the central nervous system. It is involved in translational regulation of 
target mRNA. Therefore, it is predicted that the interaction of the above novel lincRNAs and MSI1 
might have translational regulatory effect on IGF2 gene which is expressed in adult liver and central 
nervous system. [193] 
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In the other hand RBM3 protein is Cold-inducible mRNA binding protein that enhances global protein 
synthesis. It is involved in positive regulation of translation by reducing the relative abundance of 
microRNAs during overexpression. [199] Hence, this protein might be interacting with the above 
mentioned lincRNAs to regulate the translation of the gene by regulating the relative abundance of 
the miRNAs. 
 
RNA-binding protein 8A (RBM8A) is a core component of the splicing-dependent multiprotein exon 
junction complex (EJC) deposited at splice junctions on mRNAs. The EJC marks the position of the 
exon-exon junction in the mature mRNA for the gene expression machinery and the core components 
remain bound to spliced mRNAs throughout all stages of mRNA metabolism thereby influencing 
downstream processes including nuclear mRNA export, subcellular mRNA localization, translation 
efficiency and nonsense-mediated mRNA decay (NMD).[196] Thus, the interaction of this protein 
with both IGF2 gene and the novel lincRNAs might have functional significance on splicing and 
metabolism of IGF2 gene and the newly identified lincRNAs. [196] 
 
Based on the miRNA-lincRNA interaction using the miRanda software, the function of the TCGA_gbm-
22-29576001, TCGA_gbm-21-27587751 and TCGA_gbm-17-10671251 novel lincRNAs are predicted to 
influence the gene regulation by either competing for binding site on hsa-mir-181d  with its target 
genes and/or influencing the normal functioning of hsa-mir-181d.  hsa-mir-181d targets and 
modulates protein expression by inhibiting translation or inducing degradation of target messenger 
RNAs.[197] 
 
hsa-mir-210, which is linked to hypoxia pathway usually overexpressed in cells affected by cardiac 
disease and tumours, is known for its up-regulation of angiogenesis and inhibition of cardiomyocyte 
apoptosis. It has also target on TCGA_gbm-17-21730501 and TCGA_gbm-17-30454751 novel 
lincRNAs. Therefore, in one way or another the interaction of the TCGA_gbm-17-21730501 and 
TCGA_gbm-17-30454751 with hsa-mir-210 reveals the functional involvement of novel lincRNAs on 
the regulation of angiogenesis and cardiomyocyte apoptosis. [198] 
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6 DISCUSSION    
 
As the identification and discovery of the novel lncRNAs are growing due to the highly efficient and 
affordable high throughput sequencing technologies, the functional involvement of lncRNAs in 
various cellular system is the central research topic.  Recent studies have shown that the lncRNAs are 
functionally involved in transcriptional regulation, posttranscriptional regulations, translational 
regulation and RNA processing. 
 
The result from the co-expression analysis shows that TCGA_gbm--3--153501 novel lincRNA which 
co-expressed with THBS1 gene is involved in cell-cell and cell-to-matrix interactions. These highlight 
that the role of such lincRNA might be involved in chromatin remodeling by recruiting the chromatin 
modification complex.  This might also be evidence for the involvement of this lincRNA in the 
transcriptional regulation. Thus, these effect might be exhibited on platelet aggregation, 
angiogenesis, and tumorigenesis. [202] Based on the mutual information co-expression analysis, 
TCGA_gbm-21--27587751, which co-expressed with RARRES2 gene, is expected to have functional 
involvement in the initiation of chemotaxis via the ChemR23 G protein-coupled seven-
transmembrane domain ligand [205]. Chemotaxis is the movement of cells in response to the 
chemical stimuli. 
 
From the protein-DNA and protein-lincRNA interaction results, the proteins that bind to both the 
gene and lincRNAs are identified.  The top 5 highly differentially expressed novel lincRNAs and IGF2 
gene have common proteins that bind to the promoter region of the IGF2 gene. These proteins are 
MSI1, RBM3, RBM8A, BRUNOL5 and DAZAP1.  The interaction of MSI1 and RBM3 on the promoter 
regions of IGF2 gene and the novel lincRNA, which is associated with regulation of cellular 
proliferation, growth, migration, differentiation and survival, might have translational regulation by 
targeting mRNA or reducing the relative abundance of microRNAs during overexpression. [199]    
 
The interaction of RBM8A protein with the IGF2 gene and the novel lincRNA is predicted to have a 
functional significance in RNA splicing and overall process of RNA metabolism.  As a result, it 
influences downstream processes including nuclear mRNA export, subcellular mRNA localization, 
translation efficiency and nonsense-mediated mRNA decay (NMD).[196]  The fact that IGF2 gene is 
expressed in adult liver and in epithelial cells lining surface of the brain indicates that it has the 
protein interactions have significant functional roles in the glioblastoma tumorigenesis. [193] 
 
Based on the result from the miRNA-lincRNA interactions, TCGA_gbm-22-29576001, TCGA_gbm-21-
27587751 and TCGA_gbm-17-10671251 lincRNAs and hsa-mir-181d interact in such a way that it 
results in the transcriptional regulation by competing for the binding site on the miRNA with its 
target gene. In addition to that it regulates the gene expression by inhibiting translation or inducing 
degradation of target messenger RNAs. [198] The functional aspect of those interacting novel 
lincRNAs might be related to the functionalities of the interacting miRNAs or they might influence 
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the interaction between the 3’ UTR of mRNAs and miRNAs. This has a post transcriptional regulatory 
role. 
 
The efficacy of the computational functional predication of the long noncoding RNAs depends on the 
algorithmic efficiency of identifying the lncRNAs and computational methods used to predict the 
function. One of the drawback in this project is that it relayed on the Novellette algorithm [204] for 
the identification of the novel lncRNAs. The exons, polyA tails and UTR regions of lincRNA’s genomic 
coordinates from [204] are ambiguous. Thus, it has made the exact lincRNA sequence retrieval 
difficult. 
 
In the protein-DNA and protein-lincRNA interactions analysis, this project only considers the 
sequence-based approaches ignoring the secondary & tertiary structures and the van der waals 
interactions between the interacting molecules. This might be the limitation of protein-DNA and 
protein-lincRNA interactions analysis steps in this project. In addition to that, for protein-DNA 
interaction analysis, the PFM from hDPI database might not contain all of the possible protein-DNA 
interaction motifs.  In the same way, for protein-lincRNA interaction analysis, there are only 53 RBP 
motifs used from RBPDB database and 102 RBP motifs from RNAcompete database. This PFM might 
not be the only RBP motifs. Therefore, it might considered as a limitation. 
 
The future researches in the field of the functional computational prediction of long noncoding RNAs 
have to consider optimizing the algorithms used in identifications of novel lncRNAs. In addition, 
together with the gene expression, novel transcripts expression and miRNA expression, it is 
recommended to add the protein level expression on the analysis pipeline. This will give a chance to 
investigate the posttranslational effects of different interacting molecules such as the interaction of 
miRNA with lincRNA and miRNA with mRNA. The computational methods used in protein-DNA and 
protein-lincRNA interaction analysis should also consider the secondary and tertiary structures 
together with the van der waal’s interactions.    
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7 CONCLUSIONS          
Long noncoding RNAs are RNA molecules without coding potential and longer than 200 nucleotides. 
The vast majority, about 97%, of the transcribed RNAs in the genome are ncRNAs. Based on the 
genomic location and context lncRNAs are classified into long intergenic RNA (lncRNA), intronic RNA, 
sene lncRNA and anti-sense lncRNA.  Based on the effects exerted on the DNA sequence, lncRNAs are 
classified into cis-lncRNA and trans-lncRNA. Based on the cellular molecular mechanism, lncRNAs 
are grouped in transcriptional regulation, post-transcriptional regulation and other functions. Signal, 
Decoy, guide and scaffolds are types of lncRNA based on the targeting mechanism. 
 
LncRNAs are identified using both experimental and computational methods. Some of the 
experimental methods include tilling array, serial analysis of gene expression (SAGE), RNA 
sequencing (RNA-seq), RNA immunoprecipitation (RNA-IP) and chromatin signature based 
approaches. The computational approaches to identify the lncRNAs include ORF length stratagy, 
sequence and secondary structure conservation strategy, and machine learning approaches.    
 
LncRNAs function in different epigenetic regulation, transcriptional regulation of gene expression 
and in the processing of other small RNAs. They also function as structural component by interacting 
with other proteins. HOTAIR, PCAT-1 and MALAT1 are some of the lncRNAs that are associated with 
diseases such as Lung, breast, colorectal and prostate cancers.  However, some lncRNAs are being 
introduced as a potential therapeutic target and biomarker in the diagnostics and prognostics of 
different cancer types via both oncogenic and tumor-suppressive pathways. 
 
The result from different computational methods are combined to predict the novel lincRNA 
functions that are identified from TCGA glioblastoma multiforme datasets. In the analysis, the co-
expression based method and sequence based methods like protein-DNA, protein-lincRNA and 
miRNA-lincRNA interactions are considered to predict the functionality of the novel lincRNAs. As a 
result, the functional prediction of those novel lincRNAs are associated with transcriptional 
regulation by transcriptional interference, translational regulation by reducing the expression of 
miRNAs or by competing for target sites on miRNAs with mRNAs. They are also predicted to be 
involved in the RNA processing and splicing regulation. 
 
In conclusion, further researches has to be made by integrating the finding from this project and 
protein level expression to assert the posttranscriptional regulation that has been predicted in this 
project is the valid one.  In addition to that, enhancing the computational method that is used to 
identify the lncRNA by using the modern and efficient machine learning algorithms increase the 
functional prediction accuracy.  The feature research has to also consider the secondary & tertiary 
structure together with the vander waal’s interaction while analyzing the protein-DNA, protein-
lincRNA and miRNA-lincRNA interaction.   
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9 Appendix 
 
In this appendix, the R script and other files that are used in the data analysis are introduced. The 
files are available for download at https://github.com/insilicolife/Thesis_Files.git gitHub repository.  
The details of the files in the repository are explained in the table below. 
 
 
Files Description 
DEAnalyzer.r This R script performs normalization, & preprocessing 
of raw count data, differential expression analysis, 
enrichment and association analysis for gene expression 
 
DEquartileAnalyzer.r A function to analyze the differential expression based 
on quartile. 
GSEAcalculater.r A function that analyses the GSEA enrichment analysis 
LincRNASeqHg19.fasta A fasta sequence file extracted from hg19 genome 
assembly for the lincRNA sequences discovered by 
Novellette algorithm. 
MIcalculater.r A mutual information calculation function for the given 
two datasets. 
PWMSoreSerial.r R script for DNA-protein and RNA-protein motif 
scanning 
corCalculater.r R script for calculating the correlation between two 
datasets. 
enrichment.r R function that analyzes the gene-list enrichment 
analysis. 
msigdb Molecular signature database for enrichment analysis 
from board institute. 
lincRNAControlSeq.fa A fasta file that is used as a control sequence for 
protein-DNA interaction significance test. 
hPDI Directory that holds the human protein-DNA interaction 
motifs in PFM form 
53_Novel_Transcript_from_Novellette_algorith
m.xlsx 
Descriptions of lincRNAs that are identified using 
Novellette algorithm. 
miRanda-3.3a An open source software package from Memorial Sloan-
Kettering Cancer Center, New York for microRNA target 
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scanning on the reference RNA using the dynamic 
programming and thermodynamic approaches. 
miRNASeqmiRbaseDB.fasta A fasta file containing highly differentially expressed 
miRNA sequence 
reverseInteractionInDataFrameToxslx.xlsx The interaction motif scanning result of RBP that have 
common binding motifs with the reverse strand 
promoter regions of highly differentially expressed 
genes and the lincRNAs. 
forwardInteractionInDataFrameToxslx.xlsx  
The interaction motif scanning result of RBP that have 
common binding motifs with the forward strand 
promoter regions of highly differentially expressed 
genes and the lincRNAs. 
 
bothStrandInteractionInDataFrameToxslx.xls
x 
The interaction motif scanning result of RBP that have 
common binding motifs with both forward and reverse 
strand promoter regions  of highly differentially 
expressed genes and the lincRNAs. 
 
 
